The University of Chicago Header Logo

Stephen B. Hanauer

TitleEmeritus/Emerita
InstitutionUniversity of Chicago
DepartmentMedicine
AddressChicago IL 60637
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    U01DK060083     (HANAUER, STEPHEN B.)Jul 1, 2003 - Apr 30, 2008
    NIH
    Multi-site Trial of Azathioprine Dosing in Crohn Disease
    Role: Principal Investigator
    R01DK060083     (HANAUER, STEPHEN B.)Jul 1, 2003 - Apr 30, 2007
    NIH
    Multi-site Trial of Azathioprine Dosing in Crohn Disease
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hanauer SB, Colombel JF, Hanauer SB, Colombel JF. Reply. Gastroenterology. 2024 Nov 26. PMID: 39603429.
      Citations:    Fields:    
    2. Shatila M, Zhang HC, Shirwaikar Thomas A, Machado AP, Naz S, Mittal N, Catinis C, Varatharajalu K, Colli Cruz C, Lu E, Wu D, Brahmer JR, Carbonnel F, Hanauer SB, Lashner B, Schneider B, Thompson JA, Obeid M, Farris DP, Wang Y. Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events. J Immunother Cancer. 2024 Nov 14; 12(11). PMID: 39542654; PMCID: PMC11575294.
      Citations:    Fields:    Translation:Humans
    3. Narula N, Hamam H, Liu J, Wong ECL, Marshall JK, Jairath V, Hanauer SB, Reinisch W, Dulai PS, Narula N, Hamam H, Liu J, Wong ECL, Marshall JK, Reinisch W. Adaptive Steroid Tapering Impedes Corticosteroid-free Remissions Compared with Forced Tapering in Clinical Trials of Ulcerative Colitis. J Crohns Colitis. 2024 Nov 04; 18(11):1863-1869. PMID: 38869911; PMCID: PMC11532608.
      Citations: 1     Fields:    Translation:Humans
    4. Swaminathan A, Fulforth JM, Frampton CM, Borichevsky GM, Mules TC, Kilpatrick K, Choukour M, Fields P, Ramkissoon R, Helms E, Hanauer SB, Leong RW, Peyrin-Biroulet L, Siegel CA, Gearry RB. The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease. Inflamm Bowel Dis. 2024 Nov 04; 30(11):2064-2075. PMID: 38134391; PMCID: PMC11532595.
      Citations: 3     Fields:    Translation:Humans
    5. da Silva BC, Papasotiriou S, Hanauer SB. Corticosteroid Use in Randomized Clinical Trials of Biologics and Small Molecules in Inflammatory Bowel Disease: A Systematic Review. Inflamm Bowel Dis. 2024 Oct 17. PMID: 39419764.
      Citations:    Fields:    
    6. Dulai PS, Bonner LB, Sadler C, Raffals LE, Kochhar G, Lindholm P, Buckey JC, Toups GN, Rosas L, Narula N, Jairath V, Honap S, Peyrin-Biroulet L, Sands BE, Hanauer SB, Scholtens DM, Siegel CA, HBOT-UC Consortium Investigators. Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT-UC Consortium. Aliment Pharmacol Ther. 2024 Dec; 60(11-12):1512-1524. PMID: 39403018; PMCID: PMC11599782.
      Citations:    Fields:    Translation:Humans
    7. Grosen A, Bellaguarda E, Liljeqvist-Soltic I, Skytte AB, Hanauer SB, Kelsen J. Tofacitinib Does Not Impair Sperm Quality in Men With Ulcerative Colitis. Inflamm Bowel Dis. 2024 Aug 23. PMID: 39177988.
      Citations:    Fields:    
    8. Sandborn WJ, Schreiber S, Hanauer S, Nagy P, Thakur M, Bliss C, Cataldi F, Goetsch M, Gorelick KJ, Reinisch W, Vermeire S, Danese S, D'Haens G. Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2024 May 31; 18(5):708-719. PMID: 38096402; PMCID: PMC11140626.
      Citations: 3     Fields:    Translation:Humans
    9. Hanauer SB, Sands BE, Schreiber S, Danese S, Klopocka M, Kierkus J, Kulynych R, Gonciarz M, Soltysiak A, Smolinski P, Sreckovic S, Valuyskikh E, Lahat A, Horynski M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Yang S, Lee J, Lee J, Kim JM, Park G, Sandborn WJ, Colombel JF, Sardinov R. Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY). Gastroenterology. 2024 Oct; 167(5):919-933. PMID: 38788861.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    10. Verstockt B, Pivorunas V, Smaoui N, Guay H, Kennedy NA, Lin S, Hanauer SB, Ferrante M, Panés J, Al Mahi N, Goodhand JR, Bai BYH, Vermeire S. Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies. J Crohns Colitis. 2024 Apr 23; 18(4):493-505. PMID: 37801628; PMCID: PMC11037103.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    11. Harris S, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Yan J, Wu C, Hu Y, Maddux R, Wolf DC, D'Haens G. Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's Disease. Dig Dis Sci. 2024 Jun; 69(6):2044-2054. PMID: 38568396; PMCID: PMC11162376.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    12. Bui TM, Yalom LK, Ning E, Urbanczyk JM, Ren X, Herrnreiter CJ, Disario JA, Wray B, Schipma MJ, Velichko YS, Sullivan DP, Abe K, Lauberth SM, Yang GY, Dulai PS, Hanauer SB, Sumagin R. Tissue-specific reprogramming leads to angiogenic neutrophil specialization and tumor vascularization in colorectal cancer. J Clin Invest. 2024 Apr 01; 134(7). PMID: 38329810; PMCID: PMC10977994.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    13. D'Haens G, Eberhardson M, Cabrijan Z, Danese S, van den Berg R, Löwenberg M, Fiorino G, Schuurman PR, Lind G, Almqvist P, Olofsson PS, Tracey KJ, Hanauer SB, Zitnik R, Chernoff D, Levine YA. Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn's Disease Patients: A Prospective Open-label Study. J Crohns Colitis. 2023 Dec 30; 17(12):1897-1909. PMID: 37738465; PMCID: PMC10798868.
      Citations: 7     Fields:    Translation:Humans
    14. Kay J, Cross RK, Feldman SR, Park Y, Hanauer SB. Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases. Adv Ther. 2024 02; 41(2):509-533. PMID: 38110655; PMCID: PMC10838831.
      Citations: 3     Fields:    Translation:Humans
    15. Torres J, Hanauer SB. EXPLORing the Therapeutic Ceiling in Crohn's Disease: Will Combination Pave the Way? Clin Gastroenterol Hepatol. 2024 Jul; 22(7):1377-1378. PMID: 38042231.
      Citations:    Fields:    Translation:Humans
    16. Papasotiriou SD, Dumanian GA, Strong SA, Hanauer SB. Persistent perineal sinus following proctocolectomy in the inflammatory bowel disease patient. JGH Open. 2023 Nov; 7(11):740-747. PMID: 38034049; PMCID: PMC10684985.
      Citations:    
    17. Aswani-Omprakash T, Balasubramaniam M, McGarva J, Pandit A, Mutlu EA, Hanauer SB, Taft TH. Post-traumatic stress disorder symptoms are frequent among inflammatory bowel disease patients of South Asian descent-A case-control study. Indian J Gastroenterol. 2024 Feb; 43(1):244-253. PMID: 37823984.
      Citations: 1     Fields:    Translation:Humans
    18. Ganesh N, Hanauer SB, Dulai PS. The importance of predicting patient responses to monoclonal antibodies for Crohn's disease. Expert Opin Biol Ther. 2023 Jul-Dec; 23(10):941-949. PMID: 37623370.
      Citations:    Fields:    
    19. Hanauer SB. Highlights in Ulcerative Colitis From Digestive Disease Week 2023: Commentary. Gastroenterol Hepatol (N Y). 2023 Jul; 19(7 Suppl 3):13-16. PMID: 38445001; PMCID: PMC10910363.
      Citations:    
    20. Colombel JF, Sands BE, Gasink C, Adedokun OJ, Izanec J, Ma T, Gao LL, Lee SD, Targan SR, Hanauer SB, Sandborn WJ, Yeager B, Ghosh S. Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2024 01; 22(1):144-153.e2. PMID: 37391056.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    21. D'Haens G, Peyrin-Biroulet L, Marks DJB, Lisi E, Liefaard L, Beaton A, Srinivasan N, Bouma G, Prasad N, Cameron R, Kayali Z, Tarzi R, Hanauer S, Sandborn WJ. A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis. Aliment Pharmacol Ther. 2023 08; 58(3):283-296. PMID: 37323059.
      Citations:    Fields:    Translation:HumansCells
    22. Gupta N, Papasotiriou S, Hanauer S. The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease. Expert Rev Clin Immunol. 2023 Jul-Dec; 19(9):1075-1089. PMID: 37226522.
      Citations: 3     Fields:    Translation:Humans
    23. Taft TH, McGarva J, Omprakash TA, Tomasino K, Pandit A, Mutlu EA, Hanauer SB. Hospitalization Experiences and Post-traumatic Stress in Inflammatory Bowel Disease: Opportunities for Change. Inflamm Bowel Dis. 2023 05 02; 29(5):675-683. PMID: 35894686.
      Citations: 3     Fields:    Translation:Humans
    24. Hanauer S. Plain language summary of the VOLTAIRE-CD study in people with moderate-to-severe active Crohn's disease. Immunotherapy. 2022 12; 14(17):1353-1359. PMID: 36511191.
      Citations:    Fields:    Translation:Humans
    25. Hanauer S, Wang Y, Shatila M. Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther. 2023 01; 57(1):150-151. PMID: 36468245.
      Citations:    Fields:    Translation:Humans
    26. Summa KC, Hanauer SB. COVID-19 and Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2023 03; 52(1):103-113. PMID: 36813419; PMCID: PMC9618438.
      Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
    27. Shirwaikar Thomas A, Hanauer S, Wang Y. Immune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2023 04; 21(4):878-890. PMID: 36270617.
      Citations: 5     Fields:    Translation:Humans
    28. Manzanares LD, David J, Ren X, Yalom LK, Piccolo EB, Dehghan Y, David AJ, Hanauer SB, Sumagin R. Atovaquone attenuates experimental colitis by reducing neutrophil infiltration of colonic mucosa. Front Pharmacol. 2022; 13:1011115. PMID: 36313299; PMCID: PMC9614091.
      Citations: 1     
    29. Grosen A, Bellaguarda E, Liljeqvist-Soltic I, Mejlby Hansen M, Skytte AB, Julsgaard M, Hanauer SB, Kelsen J. Normal Sperm DNA Integrity in Patients With Inflammatory Bowel Disease on Ustekinumab Maintenance Therapy. Inflamm Bowel Dis. 2022 10 03; 28(10):1603-1606. PMID: 35212374.
      Citations:    Fields:    Translation:HumansCells
    30. Menter A, Cohen S, Kay J, Strand V, Gottlieb A, Hanauer S, Eduru SK, Buschke S, Lang B, Liesenfeld KH, Schaible J, McCabe D. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial. Am J Clin Dermatol. 2022 Sep; 23(5):719-728. PMID: 35934770; PMCID: PMC9464749.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    31. CORE-IBD Collaborators, Ma C, Hanzel J, Panaccione R, Sandborn WJ, D'Haens GR, Ahuja V, Bernstein CN, Bossuyt P, Bressler B, Bryant RV, Cohen B, Colombel JF, Danese S, Dignass A, Dubinsky MC, Fleshner PR, Gearry RB, Hanauer SB, Hart A, Lakatos PL, Leong RW, Ran Z, Regueiro M, Singh S, Spinelli A, Steinhart AH, Travis SP, van der Woude CJ, Yacyshyn B, Yamamoto T, Bemelman WA, Lightner AL, Rubin DT, Scherl EJ, Siegel CA, Silverberg MS, Vermeire S, Parker CE, McFarlane SC, Guizzetti L, Smith MI, Vande Casteele N, Feagan BG, Jairath V, Atreya R, Kotze PG, Kucharzik T, Magro F, Panés J, Peyrin-Biroulet L, Allez M, Louis E. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964. PMID: 35788348.
      Citations: 19     Fields:    Translation:Humans
    32. Grosen A, Bellaguarda E, Nersting J, Hvas CL, Liljeqvist-Soltic I, Stein A, Christensen LA, Ruderman EM, Brown CR, Schmiegelow K, Zhang JX, Kelsen J, Hanauer SB. Low-dose Methotrexate Therapy Does Not Affect Semen Parameters and Sperm DNA. Inflamm Bowel Dis. 2022 07 01; 28(7):1012-1018. PMID: 34463329.
      Citations: 4     Fields:    Translation:HumansCells
    33. Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Hanauer SB, Jairath V, Lewis JD, Loftus EV, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ, SEAVUE Study Group, Allez M, Danese S, Kuehbacher T. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022 06 11; 399(10342):2200-2211. PMID: 35691323.
      Citations: 63     Fields:    Translation:HumansCTClinical Trials
    34. Taft TH, Quinton S, Jedel S, Simons M, Mutlu EA, Hanauer SB. Posttraumatic Stress in Patients With Inflammatory Bowel Disease: Prevalence and Relationships to Patient-Reported Outcomes. Inflamm Bowel Dis. 2022 05 04; 28(5):710-719. PMID: 34137449; PMCID: PMC8344426.
      Citations: 10     Fields:    Translation:HumansPHPublic Health
    35. Aoun R, Hanauer S. A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2022 May; 16(5):411-423. PMID: 35400292.
      Citations: 2     Fields:    Translation:Humans
    36. Hanauer SB. Reviewing the Use of Vedolizumab for the Treatment of Patients With Crohn's Disease. Gastroenterol Hepatol (N Y). 2022 May; 18(5):287-290. PMID: 36397754; PMCID: PMC9666817.
      Citations:    
    37. Dulai PS, Rai V, Raffals LE, Lukin D, Hudesman D, Kochhar GS, Damas OM, Sauk JS, Levy AN, Tuskey A, Deepak P, Yarur AJ, Afzali A, Ananthakrishnan AN, Cross RK, Hanauer SB, Siegel CA, Sofia MA. Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel. Am J Gastroenterol. 2022 08 01; 117(8):1288-1295. PMID: 35416799; PMCID: PMC9437635.
      Citations: 3     Fields:    Translation:Humans
    38. D'Haens GR, Sandborn WJ, Loftus EV, Hanauer SB, Schreiber S, Panaccione R, Baert F, Colombel JF, Ferrante M, Armuzzi A, Zhou Q, Goteti VS, Mostafa NM, Doan TT, Petersson J, Finney-Hayward T, Song AP, Robinson AM, Danese S, Peyrin-Biroulet L, Panés J, Louis E. Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results. Gastroenterology. 2022 06; 162(7):1876-1890. PMID: 35122766.
      Citations: 19     Fields:    Translation:Humans
    39. Sattler L, Hanauer SB, Malter L. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate). Curr Gastroenterol Rep. 2021 Dec 16; 23(12):30. PMID: 34913108.
      Citations: 14     Fields:    Translation:Humans
    40. Hudesman D, Long M, Wolf D, Hanauer S, Ghosh S, Petersen A, Pondel M, Silver M, Cross R, Feagan B. P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study. Am J Gastroenterol. 2021 Dec 01; 116(Suppl 1):S9. PMID: 35006163.
      Citations:    
    41. Hudesman D, Long M, Wolf D, Hanauer S, Ghosh S, Petersen A, Pondel M, Silver M, Cross R, Feagan B. P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study. Am J Gastroenterol. 2021 Dec 01; 116(Suppl 1):S9. PMID: 37461954.
      Citations:    Fields:    
    42. Vermeire S, Lakatos PL, Ritter T, Hanauer S, Bressler B, Khanna R, Isaacs K, Shah S, Kadva A, Tyrrell H, Oh YS, Tole S, Chai A, Pulley J, Eden C, Zhang W, Feagan BG, LAUREL Study Group. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol Hepatol. 2022 01; 7(1):28-37. PMID: 34798037.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    43. Zou F, Faleck D, Thomas A, Harris J, Satish D, Wang X, Charabaty A, Ernstoff MS, Glitza Oliva IC, Hanauer S, McQuade J, Obeid M, Shah A, Richards DM, Sharon E, Wolchok J, Thompson J, Wang Y. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer. 2021 11; 9(11). PMID: 34789551; PMCID: PMC8601082.
      Citations: 44     Fields:    Translation:Humans
    44. Hamdeh S, Micic D, Hanauer S. Review article: drug-induced small bowel injury. Aliment Pharmacol Ther. 2021 12; 54(11-12):1370-1388. PMID: 34668591.
      Citations: 7     Fields:    Translation:Humans
    45. True North Study Group, Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021 09 30; 385(14):1280-1291. PMID: 34587385.
      Citations: 161     Fields:    Translation:HumansCTClinical Trials
    46. Tetangco EP, Hanauer SB. 5-ASAs Combined With a Biologic or Tofacitinib: Predetermined Cost-Effectiveness? Am J Gastroenterol. 2021 09 01; 116(9):1958-1959. PMID: 34465697.
      Citations:    Fields:    Translation:Humans
    47. Hanauer S, Liedert B, Balser S, Brockstedt E, Moschetti V, Schreiber S. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 10; 6(10):816-825. PMID: 34388360.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    48. Linson EA, Hanauer SB. Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease - the Evolving Landscape. Curr Gastroenterol Rep. 2021 Aug 02; 23(9):16. PMID: 34338892.
      Citations: 6     Fields:    Translation:Humans
    49. Pothemont K, Quinton S, Jayoushe M, Jedel S, Bedell A, Hanauer SB, Mutlu EA, Taft TH. Patient Perspectives on Medical Trauma Related to Inflammatory Bowel Disease. J Clin Psychol Med Settings. 2022 09; 29(3):596-607. PMID: 34292456.
      Citations: 5     Fields:    Translation:Humans
    50. Sandborn WJ, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Liu WJ, Petersen A, Charles L, Huang V, Usiskin K, Wolf DC, D'Haens G. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. J Crohns Colitis. 2021 Jul 05; 15(7):1120-1129. PMID: 33438008; PMCID: PMC8256627.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    51. Turner D, Hanauer SB. Which Diet for Crohn's Disease? Food for Thought on the Specific Carbohydrate Diet, Mediterranean Diet, and Beyond. Gastroenterology. 2021 09; 161(3):798-800. PMID: 34214580.
      Citations: 2     Fields:    Translation:Humans
    52. Hemperly A, Dubinsky MC, Yarur A, Afzali A, Hanauer S, Kugathasan S, Long MD, Rabizadeh S, Sockolow R, Okada L, Jain A, Abreu MT, Vande Casteele N. Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring. Crohns Colitis 360. 2021 Jul; 3(3):otab035. PMID: 36776644; PMCID: PMC9802228.
      Citations: 1     
    53. Singh A, Mahajan R, Kedia S, Dutta AK, Anand A, Bernstein CN, Desai D, Pai CG, Makharia G, Tevethia HV, Mak JW, Kaur K, Peddi K, Ranjan MK, Arkkila P, Kochhar R, Banerjee R, Sinha SK, Ng SC, Hanauer S, Verma S, Dutta U, Midha V, Mehta V, Ahuja V, Sood A. Use of thiopurines in inflammatory bowel disease: an update. Intest Res. 2022 Jan; 20(1):11-30. PMID: 33845546; PMCID: PMC8831775.
      Citations: 32     
    54. Sandborn WJ, Feagan BG, Hanauer SB, Lichtenstein GR. The Guide to Guidelines in Ulcerative Colitis: Interpretation and Appropriate Use in Clinical Practice. Gastroenterol Hepatol (N Y). 2021 Apr; 17(4 Suppl 4):3-13. PMID: 34135718; PMCID: PMC8191814.
      Citations: 6     
    55. Bui TM, Butin-Israeli V, Wiesolek HL, Zhou M, Rehring JF, Wu JD, Yang GY, Hanauer SB, Sebag JA, Sumagin R, Wiesmüller L. Neutrophils Alter DNA Repair Landscape to Impact Survival and Shape Distinct Therapeutic Phenotypes of Colorectal Cancer. Gastroenterology. 2021 07; 161(1):225-238.e15. PMID: 33753103.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    56. Sandborn WJ, Rebuck R, Wang Y, Zou B, Adedokun OJ, Gasink C, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG, Lynch JP. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. Clin Gastroenterol Hepatol. 2022 03; 20(3):578-590.e4. PMID: 33618023; PMCID: PMC8374005.
      Citations: 64     Fields:    Translation:Humans
    57. Hamdeh S, Aziz M, Altayar O, Olyaee M, Murad MH, Hanauer SB. Early vs Late Use of Anti-TNFa Therapy in Adult Patients With Crohn Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis. 2020 11 19; 26(12):1808-1818. PMID: 32064534.
      Citations: 14     Fields:    Translation:HumansPHPublic Health
    58. Yacyshyn BR, Hanauer S, Klassen P, English BA, Stauber K, Barish CF, Gilder K, Turner S, Higgins PDR. Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn's Disease. Crohns Colitis 360. 2021 Jan; 3(1):otaa089. PMID: 36777064; PMCID: PMC9802051.
      Citations: 13     
    59. Christensen B, Hanauer SB, Gibson PR, Turner JR, Hart J, Rubin DT. Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. J Crohns Colitis. 2020 Oct 05; 14(10):1345-1353. PMID: 32267926; PMCID: PMC7533894.
      Citations: 6     Fields:    Translation:Humans
    60. Schreiber S, Hanauer SB, Sandborn WJ, Barrett K. Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. J Crohns Colitis. 2020 Sep 16; 14(9):1274-1281. PMID: 32179906.
      Citations: 4     Fields:    Translation:Humans
    61. Cohen BL, Hanauer SB. Executive Summary of 'Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States'. Am J Gastroenterol. 2020 09; 115(9):1362-1366. PMID: 32826573.
      Citations:    Fields:    Translation:Humans
    62. Dean G, Hanauer S, Levitsky J. The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications. Hepatology. 2020 09; 72(3):1127-1138. PMID: 32394535.
      Citations: 17     Fields:    Translation:Humans
    63. Cohen BL, Gallinger ZR, Ha C, Holubar SD, Hou JK, Kinnucan J, Mahadevan U, Moss AC, Raffals LE, Regueiro M, Szigethy E, Wolf D, Dubinsky MC, Patel A, Shah BJ, Ehrlich OG, Hanauer SB. Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States. Inflamm Bowel Dis. 2020 08 20; 26(9):1291-1305. PMID: 32820340.
      Citations: 1     Fields:    Translation:Humans
    64. Gordon M, Grafton-Clarke C, Akobeng A, Macdonald J, Chande N, Hanauer S, Arnott I. Pancreatitis associated with azathioprine and 6-mercaptopurine use in Crohn's disease: a systematic review. Frontline Gastroenterol. 2021; 12(5):423-436. PMID: 35401955; PMCID: PMC8989005.
      Citations: 9     
    65. Meyers TJ, Weiner AB, Graff RE, Desai AS, Cooley LF, Catalona WJ, Hanauer SB, Wu JD, Schaeffer EM, Abdulkadir SA, Kundu SD, Witte JS. Association between inflammatory bowel disease and prostate cancer: A large-scale, prospective, population-based study. Int J Cancer. 2020 11 15; 147(10):2735-2742. PMID: 32399975; PMCID: PMC7577830.
      Citations: 19     Fields:    Translation:Humans
    66. Abreu MT, Okada L, Dervieux T, Luo A, Jain A, Ritter T, Hanauer SB. Use of the Endoscopic Healing Index for Monitoring of Disease Activity in Patients With Crohn's Disease in the COVID Era. Crohns Colitis 360. 2020 Apr; 2(2):otaa035. PMID: 38626274; PMCID: PMC7197619.
      Citations: 1     
    67. Hamdeh S, Micic D, Hanauer S. Drug-Induced Colitis. Clin Gastroenterol Hepatol. 2021 09; 19(9):1759-1779. PMID: 32360808.
      Citations: 8     Fields:    Translation:Humans
    68. Bellaguarda E, Hanauer S. Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol. 2020 02; 115(2):202-210. PMID: 31922959.
      Citations: 40     Fields:    Translation:Humans
    69. Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, Johanns J, Adedokun OJ, Sands BE, Rutgeerts P, de Villiers WJS, Ghosh S, Colombel JF. IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. J Crohns Colitis. 2020 Jan 01; 14(1):23-32. PMID: 31158271.
      Citations: 79     Fields:    Translation:Humans
    70. Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2019 Dec; 17(4):435-448. PMID: 31755070.
      Citations: 1     
    71. Gupta N, Hanauer SB. One man's trash-another man's treasure: fecal transplantation. Hepatobiliary Surg Nutr. 2019 Dec; 8(6):623-625. PMID: 31929989; PMCID: PMC6943020.
      Citations:    
    72. Bhattacharyya S, Xie H, Dodda A, Varady KA, Feferman L, Halline AG, Hanauer SB, Tobacman JK. Reply to critique of "A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity". Nutr Healthy Aging. 2019; 5(2):159-163. PMID: 31922053; PMCID: PMC6951440.
      Citations: 1     
    73. Hanauer S, Sandborn WJ, Colombel JF, Vermeire S, Petersson J, Kligys K, Zhou Q, Lazar A, Reinisch W. Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. J Crohns Colitis. 2019 Sep 19; 13(9):1227-1233. PMID: 30726897; PMCID: PMC6751337.
      Citations: 6     Fields:    Translation:Humans
    74. Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2019 Sep; 17(3):420-433. PMID: 31352659.
      Citations: 1     
    75. Taft TH, Quinton S, Tomasino K, Craven M, Guadagnoli L, Bedell A, Hanauer S. Letter to the Editor: Patients With Inflammatory Bowel Disease Demonstrate an Inherent Lack of Psychopathology. Inflamm Bowel Dis. 2019 08 20; 25(9):e114. PMID: 30989208; PMCID: PMC6701509.
      Citations:    Fields:    Translation:Humans
    76. Taft TH, Bedell A, Craven MR, Guadagnoli L, Quinton S, Hanauer SB. Initial Assessment of Post-traumatic Stress in a US Cohort of Inflammatory Bowel Disease Patients. Inflamm Bowel Dis. 2019 08 20; 25(9):1577-1585. PMID: 30840762; PMCID: PMC7534390.
      Citations: 26     Fields:    Translation:Humans
    77. Hanauer SB, Schreiber S. Perspectives of Clinicians in the United States and Europe on Monitoring Levels of Biologic Agents in Patients Receiving Biologic Therapies for Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 08; 17(9):1718-1723. PMID: 31255806.
      Citations:    Fields:    Translation:Humans
    78. Linson EA, Hanauer SB. More Than a Tumor Marker…A Potential Role for Alpha-Feto Protein in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 06 18; 25(7):1271-1276. PMID: 30624658.
      Citations: 3     Fields:    Translation:HumansAnimals
    79. Gupta N, Hanauer SB. Too Soon to Discard 5-ASAs? Am J Gastroenterol. 2019 03; 114(3):534-535. PMID: 30694871.
      Citations:    Fields:    Translation:Humans
    80. Butin-Israeli V, Bui TM, Wiesolek HL, Mascarenhas L, Lee JJ, Mehl LC, Knutson KR, Adam SA, Goldman RD, Beyder A, Wiesmuller L, Hanauer SB, Sumagin R. Neutrophil-induced genomic instability impedes resolution of inflammation and wound healing. J Clin Invest. 2019 02 01; 129(2):712-726. PMID: 30640176; PMCID: PMC6355304.
      Citations: 82     Fields:    Translation:HumansAnimalsCells
    81. Burns JA, Weiner AB, Catalona WJ, Li EV, Schaeffer EM, Hanauer SB, Strong S, Burns J, Hussain MHA, Kundu SD. Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol. 2019 05; 75(5):846-852. PMID: 30528221; PMCID: PMC6542355.
      Citations: 28     Fields:    Translation:Humans
    82. Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D'Haens GR, Rutgeerts PJ, Sandborn WJ, Hanauer SB, Colombel JF, Reinisch W. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019 07; 17(8):1525-1532.e1. PMID: 30267864.
      Citations: 65     Fields:    Translation:Humans
    83. Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, Woodworth DA, Zhang H, Friedman GS, Lawendy N, Quirk D, Nduaka CI, Su C. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 01; 17(1):139-147. PMID: 30012431.
      Citations: 66     Fields:    Translation:Humans
    84. Hanauer SB, Sandborn WJ, Lichtenstein GR. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary. Gastroenterology. 2019 01; 156(1):36-42. PMID: 30195449.
      Citations: 24     Fields:    Translation:Humans
    85. Calabrese E, Kucharzik T, Maconi G, Strobel D, Wilson SR, Zorzi F, Novak KL, Bruining DH, Iacucci M, Watanabe M, Lolli E, Chiaramonte C, Hanauer SB, Panaccione R, Pallone F, Ghosh S, Monteleone G, Maaser C. Real-time Interobserver Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohn's Disease: An International Multicenter Study. Inflamm Bowel Dis. 2018 08 16; 24(9):2001-2006. PMID: 29718450.
      Citations: 15     Fields:    Translation:Humans
    86. Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018 07; 48(1):65-77. PMID: 29797519; PMCID: PMC6032827.
      Citations: 63     Fields:    Translation:HumansCTClinical Trials
    87. Patel P, Yarur A, Dalal S, Sakuraba A, Rubin DT, Hanauer SB, Hanan I, Raffals LH, Cohen RD, Pekow J. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis. 2018 05 18; 24(6):1291-1297. PMID: 29506124; PMCID: PMC7190889.
      Citations:    Fields:    Translation:Humans
    88. Krugliak Cleveland N, Ollech JE, Colman RJ, Rodriquez D, Hirsch A, Cohen RD, Hanauer SB, Hart J, Hurst R, Rubin DT. Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. Clin Gastroenterol Hepatol. 2019 01; 17(1):205-206. PMID: 29751167; PMCID: PMC7034413.
      Citations: 12     Fields:    Translation:Humans
    89. Hanauer SB. Improving IBD Care: A Personalized Approach to Management. Gastroenterol Hepatol (N Y). 2018 Mar; 14(3):1-20. PMID: 29991932; PMCID: PMC6018320.
      Citations:    
    90. Friedman AB, Brown SJ, Bampton P, Barclay ML, Chung A, Macrae FA, McKenzie J, Reynolds J, Gibson PR, Hanauer SB, Sparrow MP. Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study). Aliment Pharmacol Ther. 2018 Apr; 47(8):1092-1102. PMID: 29468701.
      Citations: 14     Fields:    Translation:Humans
    91. Papamichael K, Osterman MT, Siegel CA, Melmed GY, Dubinsky MC, Colombel JF, Hanauer SB, Cheifetz AS. Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? Gastroenterology. 2018 03; 154(4):1201-1202. PMID: 29432749.
      Citations: 9     Fields:    Translation:Humans
    92. Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao LL, Davis HM, Hanauer SB, Feagan BG, Ghosh S, Sandborn WJ. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology. 2018 05; 154(6):1660-1671. PMID: 29409871.
      Citations: 87     Fields:    Translation:Humans
    93. Hanauer SB. A Never Ending STORI. Clin Gastroenterol Hepatol. 2018 07; 16(7):1034-1036. PMID: 29391270.
      Citations: 1     Fields:    Translation:Humans
    94. Krugliak Cleveland N, Huo D, Sadiq F, Sofia MA, Marks J, Cohen RD, Hanauer SB, Turner J, Hart J, Rubin DT. Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointest Endosc. 2018 May; 87(5):1304-1309. PMID: 29307473; PMCID: PMC9646239.
      Citations: 4     Fields:    Translation:Humans
    95. Colombel JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, Panaccione R, Rutgeerts P, Hanauer SB, Ghosh S, Van Assche G, Robinson AM, Lau W, Maa JF, Huang B, Pappalardo B, Read H. Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Aliment Pharmacol Ther. 2018 01; 47(2):219-228. PMID: 29159817.
      Citations: 19     Fields:    Translation:Humans
    96. Hanauer SB. Targeting Crohn's disease. Lancet. 2017 12 23; 390(10114):2742-2744. PMID: 29096947.
      Citations:    Fields:    Translation:Humans
    97. Bertha M, Bellaguara E, Kuzel T, Hanauer S. Checkpoint Inhibitor-Induced Colitis: A New Type of Inflammatory Bowel Disease? ACG Case Rep J. 2017; 4:e112. PMID: 29043290; PMCID: PMC5636906.
      Citations: 14     
    98. Hutchison AL, Meckel K, Harrington K, Deng Z, Talasila N, Rubin DT, Hanauer SB, Hurst R, Umanskiy K, Fichera A, Hart J, Dinner AR, Bissonnette M, Pekow J. miR-4728-3p Functions as a Tumor Suppressor in Ulcerative Colitis-associated Colorectal Neoplasia Through Regulation of Focal Adhesion Signaling. Inflamm Bowel Dis. 2017 08; 23(8):1328-1337. PMID: 28594651; PMCID: PMC5535754.
      Citations: 16     Fields:    Translation:HumansCells
    99. Akhuemonkhan E, Parian A, Miller K, Hanauer S, Hutfless S. Prevalence and screening for anaemia in mild to moderate Crohn's disease and ulcerative colitis in the United States, 2010-2014. BMJ Open Gastroenterol. 2017; 4(1):e000155. PMID: 28944071; PMCID: PMC5609082.
      Citations: 13     Fields:    
    100. Chang S, Hanauer S. Optimizing pharmacologic management of inflammatory bowel disease. Expert Rev Clin Pharmacol. 2017 Jun; 10(6):595-607. PMID: 28475384.
      Citations: 7     Fields:    Translation:Humans
    101. Hanauer SB. Combination Therapy for Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2017 May; 13(5):296-298. PMID: 28656027; PMCID: PMC5479343.
      Citations: 3     
    102. Hanauer SB. Targeting interleukin 23 for Crohn's disease: finding the right drug for the right patient. Lancet. 2017 04 29; 389(10080):1671-1672. PMID: 28411871.
      Citations:    Fields:    Translation:Humans
    103. Kelsen J, Hvas CL, Bellaguarda E, Hanauer SB, Grosen A. The Influence of Methotrexate Treatment on Male Fertility and Pregnancy Outcome After Paternal Exposure. Inflamm Bowel Dis. 2017 04; 23(4):561-569. PMID: 28267049.
      Citations: 19     Fields:    Translation:HumansPHPublic Health
    104. Bhattacharyya S, Shumard T, Xie H, Dodda A, Varady KA, Feferman L, Halline AG, Goldstein JL, Hanauer SB, Tobacman JK. A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity. Nutr Healthy Aging. 2017 Mar 31; 4(2):181-192. PMID: 28447072; PMCID: PMC5389019.
      Citations: 40     
    105. Chang S, Hanauer S. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2017 Mar; 15(1):53-70. PMID: 28164249.
      Citations: 2     
    106. Christensen B, Hanauer SB, Erlich J, Kassim O, Gibson PR, Turner JR, Hart J, Rubin DT. Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. Clin Gastroenterol Hepatol. 2017 Oct; 15(10):1557-1564.e1. PMID: 28238954; PMCID: PMC5618439.
      Citations: 71     Fields:    Translation:Humans
    107. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV, Dieleman LA, Katz S, Rutgeerts P, Colombel JF, UNITI–IM-UNITI Study Group. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016 11 17; 375(20):1946-1960. PMID: 27959607.
      Citations: 642     Fields:    Translation:HumansCTClinical Trials
    108. Hanauer SB. Vitamin D Levels and Outcomes in Inflammatory Bowel Disease-Which is the Chicken and Which is the Egg? Clin Gastroenterol Hepatol. 2017 02; 15(2):247-248. PMID: 27825894.
      Citations: 1     Fields:    Translation:Humans
    109. Sandborn WJ, Colombel JF, Feagan BG, Panaccione R, Hanauer S, Schreiber S, Peyrin-Biroulet L, Vermeire S, Eichner S, Huang B, Robinson AM, Pappalardo B, Ghosh S. Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016 11; 22(11):2711-2723. PMID: 27585411.
      Citations: 7     Fields:    Translation:Humans
    110. Siegel CA, Whitman CB, Spiegel BMR, Feagan B, Sands B, Loftus EV, Panaccione R, D'Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O'Morain C, Lakatos PL, McGovern DPB, Reinisch W, Kruis W, Schreiber S, Danese S, Sandborn W, Griffiths A, Moum B, Gasche C, Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L, Halfvarson J, Rogler G, Tysk C. Development of an index to define overall disease severity in IBD. Gut. 2018 02; 67(2):244-254. PMID: 27780886.
      Citations: 45     Fields:    Translation:Humans
    111. Liu K, Prasad MA, Lo A, Bellaguarda E, Strong S, Hanauer SB. Primary Adenocarcinoma of an Ileostomy in Crohn's Disease. ACG Case Rep J. 2016 Jul; 3(4):e112. PMID: 27622191; PMCID: PMC5018220.
      Citations: 3     
    112. Lee SD, Rubin DT, Sandborn WJ, Randall C, Younes Z, Schreiber S, Schwartz DA, Burakoff R, Binion D, Dassopoulos T, Arsenescu R, Gutierrez A, Scherl E, Kayhan C, Hasan I, Kosutic G, Spearman M, Sen D, Coarse J, Hanauer S. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80. PMID: 27400222; PMCID: PMC4949014.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    113. Lim WC, Wang Y, MacDonald JK, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2016 Jul 03; 7:CD008870. PMID: 27372735; PMCID: PMC6457996.
      Citations: 72     Fields:    Translation:Humans
    114. Meckel K, Li YC, Lim J, Kocherginsky M, Weber C, Almoghrabi A, Chen X, Kaboff A, Sadiq F, Hanauer SB, Cohen RD, Kwon J, Rubin DT, Hanan I, Sakuraba A, Yen E, Bissonnette M, Pekow J. Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. Am J Clin Nutr. 2016 07; 104(1):113-20. PMID: 27281309; PMCID: PMC4919525.
      Citations: 42     Fields:    Translation:Humans
    115. Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, Aranda R, Gujrathi S, Olson A, TOUCHSTONE Study Group. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. N Engl J Med. 2016 May 05; 374(18):1754-62. PMID: 27144850.
      Citations: 172     Fields:    Translation:HumansCTClinical Trials
    116. Maaser C, Zorzi F, Kannengiesser K, Hanauer SB, Bruining DH, Iacucci M, Maconi G, Novak KL, Panaccione R, Strobel D, Wilson SR, Watanabe M, Pallone F, Ghosh S, Calabrese E. Bowel Ultrasonography in the Management of Crohn's Disease. A Review with Recommendations of an International Panel of Experts. Inflamm Bowel Dis. 2016 May; 22(5):1168-83. PMID: 26958988.
      Citations: 51     Fields:    Translation:Humans
    117. Trivedi I, Holl JL, Hanauer S, Keefer L. Integrating Adolescents and Young Adults into Adult-Centered Care for IBD. Curr Gastroenterol Rep. 2016 May; 18(5):21. PMID: 27086002.
      Citations: 3     Fields:    Translation:Humans
    118. Hanauer SB. Oral or Topical 5-ASA in Ulcerative Colitis. Dig Dis. 2016; 34(1-2):122-4. PMID: 26982709.
      Citations: 6     Fields:    Translation:Humans
    119. Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P, PREVENT Study Group. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology. 2016 Jun; 150(7):1568-1578. PMID: 26946343.
      Citations: 98     Fields:    Translation:HumansPHPublic Health
    120. Colman RJ, Rodriquez D, Hirsch A, Cohen RD, Hanauer SB, Hart J, Rubin DT, Krugliak Cleveland N. Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis. 2016 Mar; 22(3):631-7. PMID: 26658214; PMCID: PMC5058785.
      Citations: 11     Fields:    Translation:HumansPHPublic Health
    121. Sandborn W, Gasink C, Blank M, Lang Y, Johanns J, Gao LL, Sands B, Hanauer S, Feagan B, Targan S, Ghosh S, de Villiers W, Colombel JF, Lee S, Desreumaux P, Loftus E, Vermeire S, Rutgeerts P. O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFNa: UNITI-1. Inflamm Bowel Dis. 2016 Mar; 22 Suppl 1:S1. PMID: 26849718.
      Citations:    
    122. D'Haens G, Bressler B, Danese S, Gibson P, Hanauer SB, Sandborn W. The Crohn's Disease-Ulcerative Colitis Clinical Appraisal. Clin Gastroenterol Hepatol. 2016 Apr; 14(4):638-9. PMID: 26850690.
      Citations:    Fields:    Translation:Humans
    123. Trivedi I, Raj R, Hanauer S. Hyperacute Methotrexate Pneumonitis in a Patient With Crohn's Disease. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):A29-30. PMID: 26592712.
      Citations: 1     Fields:    Translation:Humans
    124. Trivedi I, Hanauer SB. Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Expert Opin Drug Saf. 2015; 14(12):1915-34. PMID: 26559664.
      Citations: 2     Fields:    Translation:HumansCells
    125. Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Munkholm P, Murdoch TB, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, O'Donnell S, Winer S, Hanauer S, Colombel JF, Peyrin-Biroulet L, Marteau P, Ordás I, Panes J, Bouguen G, Pariente B. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015 Sep; 110(9):1324-38. PMID: 26303131.
      Citations: 619     Fields:    Translation:Humans
    126. Melmed GY, Pandak WM, Casey K, Abraham B, Valentine J, Schwartz D, Awais D, Bassan I, Lichtiger S, Sands B, Hanauer S, Richards R, Oikonomou I, Parekh N, Targan S, Johnson K, Hariri R, Fischkoff S. Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study. Inflamm Bowel Dis. 2015 Aug; 21(8):1809-16. PMID: 25985246.
      Citations: 33     Fields:    Translation:HumansCellsCTClinical Trials
    127. Hanauer SB. Reply: To PMID 25311382. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2384-5. PMID: 26215841.
      Citations:    Fields:    Translation:Humans
    128. Sandborn WJ, Danese S, Feagan BG, Hanauer SB, Rycroft B, Peyrin-Biroulet L, Panés J, Vermeire S, Colombel JF. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):348-354.e17. PMID: 26071941.
      Citations: 134     Fields:    Translation:Humans
    129. Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, Feagan BG, Hanauer S, Reinisch W, Valentine JF, Huang B, Carcereri R, Panaccione R. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis. 2015 Jun; 21(6):1329-40. PMID: 25989338; PMCID: PMC4450894.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    130. Travis SP, Schnell D, Feagan BG, Abreu MT, Altman DG, Hanauer SB, Krzeski P, Lichtenstein GR, Reinisch W, Sands BE, Schnell P, Yacyshyn BR, Bernhardt CA, Sandborn WJ, Marteau PR, Mary JY, Colombel JF. The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. J Crohns Colitis. 2015 Aug; 9(8):607-16. PMID: 25956538; PMCID: PMC4584567.
      Citations: 25     Fields:    Translation:Humans
    131. Lichtenstein GR, Hanauer SB, Sandborn WJ. Emerging Treatment Options in Mild to Moderate Ulcerative Colitis. Gastroenterol Hepatol (N Y). 2015 Mar; 11(3 Suppl 1):1-16. PMID: 26491415; PMCID: PMC4609145.
      Citations: 3     
    132. Hanauer SB. ACG presidential introduction. Am J Gastroenterol. 2015 Jan; 110(1):4-5. PMID: 25567163.
      Citations:    Fields:    Translation:Humans
    133. Ananthakrishnan AN, Hanauer SB. The Holy Grail, or only half way there? Gastroenterology. 2015 Jan; 148(1):8-10. PMID: 25451664.
      Citations:    Fields:    Translation:Humans
    134. Hanauer SB. Heading back to the trough (levels of biologics in IBD). Clin Gastroenterol Hepatol. 2015 Mar; 13(3):548-51. PMID: 25311382.
      Citations: 2     Fields:    Translation:Humans
    135. Stein AC, Rubin DT, Hanauer SB, Cohen RD. Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8. PMID: 25171509.
      Citations: 6     Fields:    Translation:Humans
    136. Ford AC, Luthra P, Hanauer SB, Travis SP, Harris MS, Reinisch W. Placebo response rate in clinical trials of fistulizing Crohn's disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014 Dec; 12(12):1981-90. PMID: 25218669.
      Citations: 7     Fields:    Translation:Humans
    137. Maranville JC, Micic D, Hanauer SB, Di Rienzo A, Kupfer SS. In vitro sensitivity assays and clinical response to glucocorticoids in patients with inflammatory bowel disease. J Crohns Colitis. 2014 Nov; 8(11):1539-47. PMID: 25052346; PMCID: PMC4648270.
      Citations: 7     Fields:    Translation:HumansCells
    138. Feagan BG, Colombel JF, Hanauer SB, Parikh A, Rutgeerts P, Sandborn WJ, Sands BE. Comment on 'anti-adhesion therapies and the rule of 3 for rare events'. Am J Gastroenterol. 2014 Jul; 109(7):1083-4. PMID: 24989100.
      Citations: 1     Fields:    Translation:Humans
    139. Sands BE, Feagan BG, Rutgeerts P, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S, Colombel JF. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014 Sep; 147(3):618-627.e3. PMID: 24859203.
      Citations: 265     Fields:    Translation:HumansCTClinical Trials
    140. Ho IK, Cash BD, Cohen H, Hanauer SB, Inkster M, Johnson DA, Maher MM, Rex DK, Saad A, Singh A, Rehani MM, Quigley EM. Radiation exposure in gastroenterology: improving patient and staff protection. Am J Gastroenterol. 2014 Aug; 109(8):1180-94. PMID: 24842339.
      Citations: 11     Fields:    Translation:HumansPHPublic Health
    141. Travis S, Hanauer S, Wang H, Shara N, Harris MS, Reinisch W. AST-120 (spherical carbon adsorbent) in the treatment of perianal fistulae in mild-to-moderate Crohn's disease: FHAST-1, a phase 3, multicenter, placebo-controlled study. Inflamm Bowel Dis. 2014 May; 20(5):872-81. PMID: 24694794; PMCID: PMC5175486.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    142. Sandborn WJ, Hanauer S, Van Assche G, Wilson S, Petersson J, Panaccione R, Panés J. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014 Sep; 8(9):927-35. PMID: 24713173.
      Citations: 45     Fields:    Translation:Humans
    143. Cornillie F, Hanauer SB, Diamond RH, Wang J, Tang KL, Xu Z, Rutgeerts P, Vermeire S. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014 Nov; 63(11):1721-7. PMID: 24474383; PMCID: PMC4215276.
      Citations: 122     Fields:    Translation:Humans
    144. Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-a biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013 Dec; 145(6):1464-78.e1-5. PMID: 24267475.
      Citations: 47     Fields:    Translation:Humans
    145. Hanauer SB. Still in pursuit. Gastroenterology. 2014 Jan; 146(1):13-5. PMID: 24287301.
      Citations: 1     Fields:    Translation:Humans
    146. Dassopoulos T, Dubinsky MC, Bentsen JL, Martin CF, Galanko JA, Seidman EG, Sandler RS, Hanauer SB. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther. 2014 Jan; 39(2):163-75. PMID: 24237037; PMCID: PMC3918445.
      Citations: 32     Fields:    Translation:Humans
    147. Hanauer SB, Kirsner JB. Comparing guidelines for the treatment of inflammatory bowel disease. Dig Dis. 2013; 31(3-4):360-2. PMID: 24246988.
      Citations:    Fields:    Translation:Humans
    148. Sakuraba A, Annunziata ML, Cohen RD, Hanauer SB, Rubin DT. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis. 2013 Nov; 19(12):2577-83. PMID: 24132161.
      Citations: 11     Fields:    Translation:Humans
    149. Hanauer SB. Dissecting diverticulosis database dilemmas. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1525-6. PMID: 24157249.
      Citations:    Fields:    Translation:Humans
    150. Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, Hanauer SB, Sandborn WJ, Bouguen G. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol. 2015 Jun; 13(6):1042-50.e2. PMID: 24036054.
      Citations: 101     Fields:    Translation:HumansPHPublic Health
    151. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A, GEMINI 1 Study Group, Colombel JF. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22; 369(8):699-710. PMID: 23964932.
      Citations: 920     Fields:    Translation:HumansCTClinical Trials
    152. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A, GEMINI 2 Study Group, Colombel JF. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013 Aug 22; 369(8):711-21. PMID: 23964933.
      Citations: 776     Fields:    Translation:HumansCTClinical Trials
    153. Liu W, Chen Y, Golan MA, Annunziata ML, Du J, Dougherty U, Kong J, Musch M, Huang Y, Pekow J, Zheng C, Bissonnette M, Hanauer SB, Li YC. Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J Clin Invest. 2013 Sep; 123(9):3983-96. PMID: 23945234; PMCID: PMC3754241.
      Citations: 169     Fields:    Translation:HumansAnimalsCells
    154. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Feagan BG, Hanauer SB, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Schnell P, Bernhardt CA, Mary JY, Sandborn WJ, Colombel JF. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013 Nov; 145(5):987-95. PMID: 23891974.
      Citations: 155     Fields:    Translation:Humans
    155. Rubin DT, Huo D, Kinnucan JA, Sedrak MS, McCullom NE, Bunnag AP, Raun-Royer EP, Cohen RD, Hanauer SB, Hart J, Turner JR. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1601-8.e1-4. PMID: 23872237; PMCID: PMC3840031.
      Citations: 106     Fields:    Translation:Humans
    156. Sandborn WJ, Elliott DE, Weinstock J, Summers RW, Landry-Wheeler A, Silver N, Harnett MD, Hanauer SB. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. Aliment Pharmacol Ther. 2013 Aug; 38(3):255-63. PMID: 23730956.
      Citations: 60     Fields:    Translation:HumansAnimalsCells
    157. Herfarth HH, Katz JA, Hanauer SB, Sandborn WJ, Loftus EV, Sands BE, Galanko JA, Walkup D, Isaacs KL, Martin CF, Sandler RS, Sartor RB. Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2013 Apr; 19(5):1073-9. PMID: 23511031; PMCID: PMC4596532.
      Citations: 18     Fields:    Translation:HumansPHPublic Health
    158. Pekow J, Dougherty U, Huang Y, Gometz E, Nathanson J, Cohen G, Levy S, Kocherginsky M, Venu N, Westerhoff M, Hart J, Noffsinger AE, Hanauer SB, Hurst RD, Fichera A, Joseph LJ, Liu Q, Bissonnette M. Gene signature distinguishes patients with chronic ulcerative colitis harboring remote neoplastic lesions. Inflamm Bowel Dis. 2013 Mar; 19(3):461-70. PMID: 23388545; PMCID: PMC3836269.
      Citations: 30     Fields:    Translation:HumansCells
    159. Melmed GY, Siegel CA, Spiegel BM, Allen JI, Cima R, Colombel JF, Dassopoulos T, Denson LA, Dudley-Brown S, Garb A, Hanauer SB, Kappelman MD, Lewis JD, Lynch I, Moynihan A, Rubin DT, Sartor RB, Schwartz RM, Wolf DC, Ullman TA. Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis. 2013 Mar; 19(3):662-8. PMID: 23388547.
      Citations: 58     Fields:    Translation:Humans
    160. Sakuraba A, Keyashian K, Correia C, Melek J, Cohen RD, Hanauer SB, Rubin DT. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6. PMID: 23429449; PMCID: PMC4779049.
      Citations: 14     Fields:    Translation:Humans
    161. Mayer L, Pandak WM, Melmed GY, Hanauer SB, Johnson K, Payne D, Faleck H, Hariri RJ, Fischkoff SA. Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant crohn's disease: a phase 1 study. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):754-60. PMID: 23429460; PMCID: PMC4272923.
      Citations: 29     Fields:    Translation:HumansCellsCTClinical Trials
    162. Hoentjen F, Seinen ML, Hanauer SB, de Boer NK, Rubin DT, Bouma G, Harrell LE, van Bodegraven AA. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Feb; 19(2):363-9. PMID: 22605661.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    163. Kinnucan JA, Hanauer SB. Reassessing the risks and benefits of thiopurines in Crohn's disease. Clin Gastroenterol Hepatol. 2013 Apr; 11(4):395-7. PMID: 23333707.
      Citations:    Fields:    Translation:Humans
    164. Hoentjen F, Hanauer SB, Hart J, Rubin DT. Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-enteritis after colectomy. J Clin Gastroenterol. 2013 Jan; 47(1):52-7. PMID: 22858512; PMCID: PMC3874322.
      Citations: 13     Fields:    Translation:Humans
    165. Hanauer SB, Rubin DT. Joseph Barnett Kirsner, MD, PhD. Dig Dis Sci. 2012 Nov; 57(11):2722-4. PMID: 23236606.
      Citations:    Fields:    Translation:Humans
    166. Hanauer SB, Rubin DT. Joseph Barnett Kirsner, MD, PhD. Clin Gastroenterol Hepatol. 2012 Nov; 10(11):1181-2. PMID: 23084570.
      Citations:    Fields:    Translation:Humans
    167. Hanauer SB, Rubin DT. In memoriam. Inflamm Bowel Dis. 2012 Nov; 18(11):2001-3. PMID: 23070951.
      Citations:    Fields:    Translation:Humans
    168. Lichtenstein GR, Hanauer SB, Sandborn WJ. Risk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's Disease. Gastroenterol Hepatol (N Y). 2012 Nov; 8(11 Suppl 8):1-20. PMID: 24847181; PMCID: PMC4027896.
      Citations: 2     
    169. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG, CERTIFI Study Group. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012 Oct 18; 367(16):1519-28. PMID: 23075178.
      Citations: 413     Fields:    Translation:HumansCTClinical Trials
    170. Calabrese E, Hanauer SB. Reply to Dr Kountouras et al.'s letter. J Crohns Colitis. 2013 Jul; 7(6):515. PMID: 23062329.
      Citations:    Fields:    Translation:Humans
    171. Hanauer SB, Rubin D. Joseph Barnett Kirsner, MD, PhD. Gastrointest Endosc. 2012 Oct; 76(4):730-2. PMID: 22985640.
      Citations:    Fields:    
    172. Hanauer SB, Rubin DT. In memoriam: Dr Joseph Barnett Kirsner. Gut. 2012 Nov; 61(11):1636-7. PMID: 22976043.
      Citations:    Fields:    Translation:Humans
    173. Hanauer SB. What to take from TREAT? Am J Gastroenterol. 2012 Sep; 107(9):1423-5. PMID: 22951879.
      Citations: 1     Fields:    Translation:Humans
    174. Pekow J, Li YC, Hanauer SB. Association between higher predicted serum vitamin D levels and reduced incidence of inflammatory bowel diseases. Gastroenterology. 2012 Sep; 143(3):e28. PMID: 22841731.
      Citations:    Fields:    Translation:Humans
    175. Hanauer SB, Kirsner JB. Treat the patient or treat the disease? Dig Dis. 2012; 30(4):400-3. PMID: 22796805.
      Citations: 9     Fields:    Translation:Humans
    176. Sands BE, Katz S, Wolf DC, Feagan BG, Wang T, Gustofson LM, Wong C, Vandervoort MK, Hanauer S. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. Gut. 2013 Sep; 62(9):1288-94. PMID: 22760005.
      Citations: 16     Fields:    Translation:HumansCells
    177. Kaufman AB, Hanauer SB. Commentary: pre-operative use of anti-TNF-a agents and the risk of post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther. 2012 Jul; 36(2):199-200; discussion 200. PMID: 22703456.
      Citations:    Fields:    Translation:Humans
    178. Hanauer SB. Disease modification in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012 Sep; 10(9):954-5. PMID: 22728318.
      Citations: 1     Fields:    Translation:Humans
    179. Hoentjen F, Colwell JC, Hanauer SB. Complications of peristomal recurrence of Crohn's disease: a case report and a review of literature. J Wound Ostomy Continence Nurs. 2012 May-Jun; 39(3):297-301. PMID: 22552106.
      Citations: 6     Fields:    Translation:Humans
    180. Keyashian K, Annunziata ML, Sakuraba A, Hanauer S. Management of inflammatory bowel disease: past, present and future. Expert Rev Clin Immunol. 2012 May; 8(4):303-5. PMID: 22607175.
      Citations: 3     Fields:    Translation:Humans
    181. Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R, Gujrathi S, Luo A, Peng Y, Salter-Cid L, Hanauer SB. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology. 2012 Jul; 143(1):62-69.e4. PMID: 22504093.
      Citations: 57     Fields:    Translation:Humans
    182. Harrell L, Wang Y, Antonopoulos D, Young V, Lichtenstein L, Huang Y, Hanauer S, Chang E. Standard colonic lavage alters the natural state of mucosal-associated microbiota in the human colon. PLoS One. 2012; 7(2):e32545. PMID: 22389708; PMCID: PMC3289660.
      Citations: 69     Fields:    Translation:Humans
    183. Leung Y, Kaplan GG, Rioux KP, Hubbard J, Kamhawi S, Stasiak L, Cohen RD, Devlin SM, Panaccione R, Hanauer SB, Rubin DT. Assessment of variables associated with smoking cessation in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1026-32. PMID: 22311366.
      Citations: 8     Fields:    Translation:Humans
    184. Annunziata ML, Hanauer S. Can we treat ulcerative colitis with nutritional supplements? Aliment Pharmacol Ther. 2012 Feb; 35(4):485; author reply 486-7. PMID: 22248423.
      Citations:    Fields:    Translation:Humans
    185. Baumgart DC, Ghosh S, Hanauer S, Hart A, Irving P, Louis E, Gomollón F. What changes in inflammatory bowel disease management can be implemented today? J Crohns Colitis. 2012 Feb; 6 Suppl 2:S260-7. PMID: 22463933.
      Citations: 2     Fields:    Translation:Humans
    186. Calabrese E, Yanai H, Shuster D, Rubin DT, Hanauer SB. Low-dose smoking resumption in ex-smokers with refractory ulcerative colitis. J Crohns Colitis. 2012 Aug; 6(7):756-62. PMID: 22398093.
      Citations: 15     Fields:    Translation:Humans
    187. Hoentjen F, Hanauer SB, de Boer NK, Rubin DT. Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction. Dig Dis Sci. 2012 Jan; 57(1):250-3. PMID: 22147254; PMCID: PMC3253335.
      Citations: 1     Fields:    Translation:Humans
    188. Ford AC, Khan KJ, Sandborn WJ, Hanauer SB, Moayyedi P. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 2012 May; 10(5):513-9. PMID: 22083024.
      Citations: 11     Fields:    Translation:HumansPHPublic Health
    189. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Feagan BG, Hanauer SB, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Bernhardt CA, Mary JY, Sandborn WJ, Colombel JF, Lémann M. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012 Apr; 61(4):535-42. PMID: 21997563; PMCID: PMC3292713.
      Citations: 171     Fields:    Translation:Humans
    190. Hoentjen F, Sakuraba A, Hanauer S. Update on the management of ulcerative colitis. Curr Gastroenterol Rep. 2011 Oct; 13(5):475-85. PMID: 21789495.
      Citations: 6     Fields:    Translation:HumansCells
    191. Sandborn WJ, Hanauer S, Lichtenstein GR, Safdi M, Edeline M, Scott Harris M. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies. Aliment Pharmacol Ther. 2011 Oct; 34(7):747-56. PMID: 21848857.
      Citations: 9     Fields:    Translation:Humans
    192. Annunziata ML, Hanauer SB. Calcineurin inhibition in severe ulcerative colitis: lost in translation? Inflamm Bowel Dis. 2012 May; 18(5):809-11. PMID: 21837776.
      Citations: 1     Fields:    Translation:Humans
    193. Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ, Colombel JF, Oddens BJ. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011 Oct; 141(4):1194-201. PMID: 21723220.
      Citations: 319     Fields:    Translation:Humans
    194. Kamm MA, Hanauer SB, Panaccione R, Colombel JF, Sandborn WJ, Pollack PF, Zhou Q, Robinson AM. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2011 Aug; 34(3):306-17. PMID: 21645018.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    195. Pekow JR, Dougherty U, Mustafi R, Zhu H, Kocherginsky M, Rubin DT, Hanauer SB, Hart J, Chang EB, Fichera A, Joseph LJ, Bissonnette M. miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis. 2012 Jan; 18(1):94-100. PMID: 21557394; PMCID: PMC3931730.
      Citations: 55     Fields:    Translation:HumansCells
    196. Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Blank M, Lang Y, Johanns J, Present D, Sands BE, Colombel JF. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012 Feb; 18(2):201-11. PMID: 21484965.
      Citations: 56     Fields:    Translation:Humans
    197. Kavanaugh AF, Mayer LF, Cush JJ, Hanauer SB. Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease. Am J Med. 2011 Apr; 124(4 Suppl):e1-18. PMID: 21531240.
      Citations: 3     Fields:    Translation:Humans
    198. Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P, American College of Gastroenterology IBD Task Force. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011 Apr; 106 Suppl 1:S2-25; quiz S26. PMID: 21472012.
      Citations: 99     Fields:    Translation:HumansPHPublic Health
    199. Cohen RD, Lewis JR, Turner H, Harrell LE, Hanauer SB, Rubin DT. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6. PMID: 21456032.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    200. Feagan BG, Hanauer SB, Coteur G, Schreiber S. Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol. Aliment Pharmacol Ther. 2011 May; 33(10):1143-51. PMID: 21443536.
      Citations: 1     Fields:    Translation:Humans
    201. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011 Apr; 106(4):685-98. PMID: 21427713.
      Citations: 121     Fields:    Translation:Humans
    202. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):644-59, quiz 660. PMID: 21407183.
      Citations: 210     Fields:    Translation:HumansPHPublic Health
    203. Kamm MA, Ng SC, De Cruz P, Allen P, Hanauer SB. Practical application of anti-TNF therapy for luminal Crohn's disease. Inflamm Bowel Dis. 2011 Nov; 17(11):2366-91. PMID: 21337669.
      Citations: 4     Fields:    Translation:Humans
    204. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun; 60(6):780-7. PMID: 21209123.
      Citations: 306     Fields:    Translation:Humans
    205. Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2010 Dec 08; (12):CD008870. PMID: 21154400.
      Citations: 42     Fields:    Translation:Humans
    206. Hanauer SB, Kornbluth AA, Messick J, Rubin DT, Sandborn WJ, Sands BE. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010 Dec; 16 Suppl 1:S1-11. PMID: 21104734.
      Citations: 8     Fields:    Translation:Humans
    207. Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ, Thomsen OØ. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011 Jan; 33(2):185-93. PMID: 21083671.
      Citations: 50     Fields:    Translation:Humans
    208. D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Quary A, Sands B, Sood A, Watermeyer G, Watermayer G, Lashner B, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Travis S, Löfberg R, Lémann M, Colombel JF. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011 Feb; 106(2):199-212; quiz 213. PMID: 21045814.
      Citations: 145     Fields:    Translation:Humans
    209. Calabrese E, Hanauer SB. Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease. J Crohns Colitis. 2011 Feb; 5(1):48-53. PMID: 21272804.
      Citations: 9     Fields:    Translation:Humans
    210. Hanauer SB. The role of biologics in ulcerative colitis. Dig Dis. 2010; 28(3):497-500. PMID: 20926878.
      Citations: 2     Fields:    Translation:Humans
    211. Pekow JR, Hetzel JT, Rothe JA, Hanauer SB, Turner JR, Hart J, Noffsinger A, Huo D, Rubin DT. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2010 Aug; 16(8):1352-6. PMID: 20027656; PMCID: PMC3046461.
      Citations: 24     Fields:    Translation:HumansPHPublic Health
    212. Hanauer SB, Hommes DW. Inflammatory bowel disease. Expert Rev Clin Immunol. 2010 Jul; 6(4):499-500. PMID: 20594118.
      Citations:    Fields:    Translation:Humans
    213. Hanauer SB. Ashes to ashes. Nat Rev Gastroenterol Hepatol. 2010 Jun; 7(6):299. PMID: 20523348.
      Citations:    Fields:    Translation:Humans
    214. Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther. 2010 Aug; 32(3):384-93. PMID: 20491747.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    215. Lodolce JP, Kolodziej LE, Rhee L, Kariuki SN, Franek BS, McGreal NM, Logsdon MF, Bartulis SJ, Perera MA, Ellis NA, Adams EJ, Hanauer SB, Jolly M, Niewold TB, Boone DL. African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity. J Immunol. 2010 Jun 15; 184(12):7001-9. PMID: 20483768; PMCID: PMC3307531.
      Citations: 59     Fields:    Translation:HumansCells
    216. Hanauer SB. Penultimate. Nat Rev Gastroenterol Hepatol. 2010 May; 7(5):237. PMID: 20442729.
      Citations:    Fields:    Translation:Humans
    217. Sandborn WJ, Schreiber S, Hanauer SB, Bloomfield R, Lichtenstein GR, PRECiSE 4 Study Investigators, Colombel JF. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):696-702.e1. PMID: 20363366.
      Citations: 13     Fields:    Translation:Humans
    218. Hanauer SB. Another vacation, another medical 'crisis'. Nat Rev Gastroenterol Hepatol. 2010 Apr; 7(4):179. PMID: 20376088.
      Citations:    Fields:    Translation:Humans
    219. Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE, Salzberg BA, Buchman AL, Mechkov GM, Krastev ZA, Lowder JN, Frankel MB, Sandborn WJ, Baumgart DC. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2010 Apr; 16(4):620-9. PMID: 19714757.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    220. Hanauer SB. Devolving therapeutic pyramids. Nat Rev Gastroenterol Hepatol. 2010 Mar; 7(3):119-20. PMID: 20203676.
      Citations:    Fields:    Translation:Humans
    221. Lichtenstein GR, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ, Precise 3 Study Investigators, Thomsen OØ. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol. 2010 Jul; 8(7):600-9. PMID: 20117244.
      Citations: 31     Fields:    Translation:Humans
    222. Hanauer SB. The expanding role of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010 Feb; 7(2):63-4. PMID: 20134483.
      Citations: 8     Fields:    Translation:Humans
    223. Hanauer SB. A poor view from specialty silos. Nat Rev Gastroenterol Hepatol. 2010 Jan; 7(1):1-2. PMID: 20051965.
      Citations: 2     Fields:    Translation:Humans
    224. Sparrow MP, Irving PM, Hanauer SB. Optimizing conventional therapies for inflammatory bowel disease. Curr Gastroenterol Rep. 2009 Dec; 11(6):496-503. PMID: 19903426.
      Citations: 2     Fields:    Translation:Humans
    225. Hanauer SB. Indecent exposures. Nat Rev Gastroenterol Hepatol. 2009 Dec; 6(12):685. PMID: 19946299.
      Citations:    Fields:    Translation:HumansPHPublic Health
    226. Hanauer SB. Medical management of Crohn's disease: treatment algorithms 2009. Dig Dis. 2009; 27(4):536-41. PMID: 19897971.
      Citations: 2     Fields:    Translation:Humans
    227. Hanauer SB. Great (cultural) expectations. Nat Rev Gastroenterol Hepatol. 2009 Nov; 6(11):623. PMID: 19881511.
      Citations:    Fields:    Translation:Humans
    228. Hanauer SB. Positioning biologic agents in the treatment of Crohn's disease. Inflamm Bowel Dis. 2009 Oct; 15(10):1570-82. PMID: 19309716.
      Citations: 5     Fields:    Translation:Humans
    229. Hanauer SB. The wrong end of the scope. Nat Rev Gastroenterol Hepatol. 2009 Oct; 6(10):559. PMID: 19789569.
      Citations:    Fields:    Translation:Humans
    230. Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009 Dec; 137(6):1934-43.e1-3. PMID: 19766640.
      Citations: 57     Fields:    Translation:Humans
    231. Hanauer SB. Exploring the controversial themes of IBD. Inflamm Bowel Dis. 2009 Sep; 15 Suppl 1:S1-10. PMID: 19693963.
      Citations:    Fields:    Translation:Humans
    232. Afif W, Leighton JA, Hanauer SB, Loftus EV, Faubion WA, Pardi DS, Tremaine WJ, Kane SV, Bruining DH, Cohen RD, Rubin DT, Hanson KA, Sandborn WJ. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7. PMID: 19408340.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    233. Hanauer S. Don't miss the forest for the trees. Inflamm Bowel Dis. 2009 Sep; 15(9):1397-8. PMID: 19591133.
      Citations:    Fields:    Translation:HumansPHPublic Health
    234. Hanauer SB. Addicted to acid suppression. Nat Rev Gastroenterol Hepatol. 2009 Sep; 6(9):497. PMID: 19713979.
      Citations: 1     Fields:    Translation:Humans
    235. Hanauer SB. Quid pro quo and the pharmascolds. Nat Rev Gastroenterol Hepatol. 2009 Aug; 6(8):437. PMID: 19654595.
      Citations:    Fields:    Translation:Humans
    236. Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009 Oct; 137(4):1250-60; quiz 1520. PMID: 19596014.
      Citations: 140     Fields:    Translation:Humans
    237. Hanauer SB. The burdens of digestive diseases. Nat Rev Gastroenterol Hepatol. 2009 Jul; 6(7):377. PMID: 19575019.
      Citations: 3     Fields:    Translation:Humans
    238. Hanauer SB, Plevy SE, Sands BE, Targan SR. Therapeutic Targets for Emerging Biologic Therapies in IBD. Gastroenterol Hepatol (N Y). 2009 Jul; 5(7 Suppl 16):4-16. PMID: 37967429; PMCID: PMC2886434.
      Citations:    
    239. Hanauer SB, Lichtenstein GR, Kamm MA, Sandborn WJ, Lees KH, Barrett K, Karlstadt RG, Diebold R, Joseph RE. MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis. Gastroenterol Hepatol (N Y). 2009 Jul; 5(7):494-500. PMID: 37967434; PMCID: PMC2886429.
      Citations: 3     
    240. Deltenre P, Ardizzone S, D'Haens G, Hanauer SB, Herfarth H, Peyrin-Biroulet L, Lémann M, Colombel JF. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol. 2009 Aug; 104(8):2089-96. PMID: 19568226.
      Citations: 56     Fields:    Translation:Humans
    241. Yun L, Hanauer S. Selecting appropriate anti-TNF agents in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2009 Jun; 3(3):235-48. PMID: 19485806.
      Citations: 7     Fields:    Translation:Humans
    242. Hanauer SB. Keep your cool: burn calories. Nat Rev Gastroenterol Hepatol. 2009 Jun; 6(6):315. PMID: 19494818.
      Citations:    Fields:    Translation:HumansAnimals
    243. Leung Y, Hanauer SB. Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow? Gastroenterol Clin Biol. 2009 Jun; 33 Suppl 3:S202-8. PMID: 20117343.
      Citations: 2     Fields:    Translation:Humans
    244. Abreu MT, von Tirpitz C, Hardi R, Kaatz M, Van Assche G, Rutgeerts P, Bisaccia E, Goerdt S, Hanauer S, Knobler R, Mannon P, Mayer L, Ochsenkuhn T, Sandborn WJ, Parenti D, Lee K, Reinisch W, Crohn's Disease Photopheresis Study Group. Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Inflamm Bowel Dis. 2009 Jun; 15(6):829-36. PMID: 19130617.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    245. Hanauer SB, Present DH, Rubin DT. Emerging issues in ulcerative colitis and ulcerative proctitis: individualizing treatment to maximize outcomes. Gastroenterol Hepatol (N Y). 2009 Jun; 5(6 Suppl):4-16. PMID: 20574506; PMCID: PMC2886411.
      Citations: 4     
    246. Hanauer SB. More food for thought. Nat Rev Gastroenterol Hepatol. 2009 May; 6(5):253. PMID: 19404262.
      Citations:    Fields:    Translation:HumansPHPublic Health
    247. Hanauer SB. Outsourcing clinical trials. Nat Rev Gastroenterol Hepatol. 2009 Apr; 6(4):191. PMID: 19347005.
      Citations: 4     Fields:    Translation:Humans
    248. Pena Rossi C, Hanauer SB, Tomasevic R, Hunter JO, Shafran I, Graffner H. Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. BMC Gastroenterol. 2009 Mar 20; 9:22. PMID: 19302707; PMCID: PMC2674451.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    249. Leung Y, Sparrow MP, Schwartz M, Hanauer SB. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J Crohns Colitis. 2009 Sep; 3(3):162-7. PMID: 21172265.
      Citations: 23     Fields:    
    250. Hanauer SB. A perfect storm. Nat Clin Pract Gastroenterol Hepatol. 2009 Mar; 6(3):127. PMID: 19259107.
      Citations:    Fields:    
    251. Hanauer SB. Tyler, Faecalibacterium and biodiversity. Nat Clin Pract Gastroenterol Hepatol. 2009 Feb; 6(2):63. PMID: 19194380.
      Citations: 1     Fields:    Translation:Humans
    252. Lichtenstein GR, Hanauer SB, Sandborn WJ, Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009 Feb; 104(2):465-83; quiz 464, 484. PMID: 19174807.
      Citations: 282     Fields:    Translation:Humans
    253. Hanauer SB. Sarcopenia and the elusive fountain of youth. Nat Clin Pract Gastroenterol Hepatol. 2009 Jan; 6(1):1. PMID: 19127276.
      Citations:    Fields:    Translation:Humans
    254. Thia KT, Sandborn WJ, Lewis JD, Loftus EV, Feagan BG, Steinhart AH, Hanauer SB, Persson T, Sands BE. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol. 2008 Dec; 103(12):3123-31. PMID: 18786111.
      Citations: 16     Fields:    Translation:Humans
    255. Hanauer SB. Biologic therapy for inflammatory bowel disease comes of age. Curr Gastroenterol Rep. 2008 Dec; 10(6):565-6. PMID: 19006611.
      Citations:    Fields:    
    256. Hanauer SB. Early aggressive therapy for Crohn's disease. Curr Gastroenterol Rep. 2008 Dec; 10(6):566-7. PMID: 19006612.
      Citations:    Fields:    
    257. Hanauer SB. Sitting on the fence. Nat Clin Pract Gastroenterol Hepatol. 2008 Dec; 5(12):655. PMID: 19039325.
      Citations:    Fields:    Translation:Humans
    258. Hanauer SB. Conflicts. Nat Clin Pract Gastroenterol Hepatol. 2008 Nov; 5(11):589. PMID: 18974750.
      Citations:    Fields:    Translation:Humans
    259. Hanauer SB. The ethics of phase I trials of biologic agents. Nat Clin Pract Gastroenterol Hepatol. 2008 Oct; 5(10):533. PMID: 18827830.
      Citations: 1     Fields:    Translation:Humans
    260. Perera MA, Thirumaran RK, Cox NJ, Hanauer S, Das S, Brimer-Cline C, Lamba V, Schuetz EG, Ratain MJ, Di Rienzo A. Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. Pharmacogenomics J. 2009 Feb; 9(1):49-60. PMID: 18825162; PMCID: PMC2754748.
      Citations: 12     Fields:    Translation:HumansCells
    261. Hanauer SB. Modifying risk factors: do the means justify the ends? Nat Clin Pract Gastroenterol Hepatol. 2008 Sep; 5(9):475. PMID: 18758470.
      Citations:    Fields:    Translation:HumansPHPublic Health
    262. Hanauer SB. Mea culpa. Nat Clin Pract Gastroenterol Hepatol. 2008 Aug; 5(8):409. PMID: 18670441.
      Citations:    Fields:    Translation:Humans
    263. Hanauer SB. Jet lag: life in the fast (and feast) lane. Nat Clin Pract Gastroenterol Hepatol. 2008 Jul; 5(7):349. PMID: 18596828.
      Citations: 1     Fields:    Translation:Humans
    264. Hanauer SB. Deadlines. Nat Clin Pract Gastroenterol Hepatol. 2008 Jun; 5(6):291. PMID: 18523481.
      Citations:    Fields:    Translation:Humans
    265. Hanauer SB. Flat polyps depress gastroenterologists. Nat Clin Pract Gastroenterol Hepatol. 2008 May; 5(5):231. PMID: 18446188.
      Citations:    Fields:    Translation:HumansPHPublic Health
    266. Sands BE, Sandborn WJ, Feagan B, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S, Adacolumn Study Group, Löfberg R. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008 Aug; 135(2):400-9. PMID: 18602921.
      Citations: 62     Fields:    Translation:HumansCells
    267. Hanauer SB. An ounce of prevention. Nat Clin Pract Nephrol. 2008 Apr; 4(4):173. PMID: 18383614.
      Citations:    Fields:    Translation:Humans
    268. Hanauer SB. Experienced pleasantness. Nat Clin Pract Gastroenterol Hepatol. 2008 Mar; 5(3):119. PMID: 18317459.
      Citations:    Fields:    Translation:HumansCells
    269. Hanauer SB. Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther. 2008 Mar; 27 Suppl 1:15-21. PMID: 18307645.
      Citations: 12     Fields:    Translation:Humans
    270. Hanauer SB. Semantics. Nat Clin Pract Gastroenterol Hepatol. 2008 Feb; 5(2):59. PMID: 18253136.
      Citations:    Fields:    Translation:Humans
    271. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol. 2008 Jan 21; 14(3):354-77. PMID: 18200659; PMCID: PMC2679125.
      Citations: 79     Fields:    Translation:HumansAnimals
    272. Hanauer SB. The role of loperamide in gastrointestinal disorders. Rev Gastroenterol Disord. 2008; 8(1):15-20. PMID: 18477966.
      Citations: 23     Fields:    Translation:Humans
    273. Shah SB, Hanauer SB. Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease. Rev Gastroenterol Disord. 2008; 8(3):159-68. PMID: 18957923.
      Citations: 2     Fields:    Translation:Humans
    274. Hanauer SB. Subgroups. Nat Clin Pract Gastroenterol Hepatol. 2008 Jan; 5(1):1. PMID: 18174903.
      Citations:    Fields:    Translation:Humans
    275. Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz JA, Lashner B, Present DH, Chuai S, Ellenberg JH, Nessel L, Wu GD, Rosiglitazone for Ulcerative Colitis Study Group. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008 Mar; 134(3):688-95. PMID: 18325386; PMCID: PMC2276587.
      Citations: 107     Fields:    Translation:Humans
    276. Hanauer SB. Biologic therapy for inflammatory bowel disease comes of age. Curr Gastroenterol Rep. 2007 Dec; 9(6):485-7. PMID: 18377800.
      Citations:    Fields:    
    277. Hanauer SB. Immunosuppressive therapy in the formation of antibodies to infliximab in Crohn's disease. Curr Gastroenterol Rep. 2007 Dec; 9(6):487-8. PMID: 18377801.
      Citations:    Fields:    
    278. Hanauer SB. My favorite topic...health. Nat Clin Pract Gastroenterol Hepatol. 2007 Dec; 4(12):641. PMID: 18043674.
      Citations:    Fields:    Translation:Humans
    279. Hanauer SB, Sandborn WJ, Dallaire C, Archambault A, Yacyshyn B, Yeh C, Smith-Hall N. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol. 2007 Dec; 21(12):827-34. PMID: 18080055; PMCID: PMC2658575.
      Citations: 52     Fields:    Translation:Humans
    280. Hanauer SB. An ounce of prevention. Nat Clin Pract Gastroenterol Hepatol. 2007 Nov; 4(11):583. PMID: 17978816.
      Citations:    Fields:    Translation:HumansPHPublic Health
    281. Isaacs KL, Sandler RS, Abreu M, Picco MF, Hanauer SB, Bickston SJ, Present D, Farraye FA, Wolf D, Sandborn WJ, Crohn's and Colitis Foundation of America Clinical Alliance. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2007 Oct; 13(10):1250-5. PMID: 17567869.
      Citations: 37     Fields:    Translation:Humans
    282. Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut. 2007 Sep; 56(9):1181-3. PMID: 17698862; PMCID: PMC1954967.
      Citations: 13     Fields:    Translation:Humans
    283. Hanauer SB. More likely than not. Nat Clin Pract Gastroenterol Hepatol. 2007 Sep; 4(9):469. PMID: 17768393.
      Citations:    Fields:    Translation:Humans
    284. Navarro FA, Hanauer SB, Kirschner BS. Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease. J Pediatr Gastroenterol Nutr. 2007 Sep; 45(3):312-8. PMID: 17873743.
      Citations: 2     Fields:    Translation:Humans
    285. Plevy S, Salzberg B, Van Assche G, Regueiro M, Hommes D, Sandborn W, Hanauer S, Targan S, Mayer L, Mahadevan U, Frankel M, Lowder J. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology. 2007 Nov; 133(5):1414-22. PMID: 17920064.
      Citations: 34     Fields:    Translation:HumansCellsCTClinical Trials
    286. Hanauer SB. Parallel universes. Nat Clin Pract Gastroenterol Hepatol. 2007 Aug; 4(8):411. PMID: 17667991.
      Citations:    Fields:    Translation:Humans
    287. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, PRECISE 2 Study Investigators, Thomsen OØ. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007 Jul 19; 357(3):239-50. PMID: 17634459.
      Citations: 261     Fields:    Translation:Humans
    288. Hanauer SB. Where do our priorities lie? Nat Clin Pract Gastroenterol Hepatol. 2007 Jul; 4(7):353. PMID: 17607292.
      Citations:    Fields:    Translation:Humans
    289. Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P, Sandborn WJ, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology. 2007 Jul; 133(1):312-39. PMID: 17631151.
      Citations: 66     Fields:    Translation:Humans
    290. Hanauer SB. Moving ahead or falling behind? Nat Clin Pract Gastroenterol Hepatol. 2007 Jun; 4(6):295. PMID: 17541443.
      Citations:    Fields:    Translation:Humans
    291. Hanauer SB, Wald A. Acute and chronic megacolon. Curr Treat Options Gastroenterol. 2007 Jun; 10(3):237-47. PMID: 17547862.
      Citations: 11     
    292. Tuvlin JA, Raza SS, Bracamonte S, Julian C, Hanauer SB, Nicolae DL, King AC, Cho JH. Smoking and inflammatory bowel disease: trends in familial and sporadic cohorts. Inflamm Bowel Dis. 2007 May; 13(5):573-9. PMID: 17345609.
      Citations: 20     Fields:    Translation:Humans
    293. Hanauer SB, DuPont HL, Cooper KM, Laudadio C. Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort. Curr Med Res Opin. 2007 May; 23(5):1033-43. PMID: 17519069.
      Citations: 9     Fields:    Translation:Humans
    294. Hanauer SB. Uncertainty. Nat Clin Pract Gastroenterol Hepatol. 2007 May; 4(5):235. PMID: 17476206.
      Citations:    Fields:    Translation:Humans
    295. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF, Colombel JF. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007 Jun 19; 146(12):829-38. PMID: 17470824.
      Citations: 255     Fields:    Translation:Humans
    296. Rubin DT, Rothe JA, Hetzel JT, Cohen RD, Hanauer SB. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007 Jun; 65(7):998-1004. PMID: 17451704.
      Citations: 51     Fields:    Translation:HumansPHPublic Health
    297. Hanauer SB. Balancing drug availability and patient safety. Nat Clin Pract Nephrol. 2007 Apr; 3(4):177. PMID: 17396284.
      Citations:    Fields:    
    298. Hanauer SB. Back to basics: food for thought--and nutrition. Nat Clin Pract Gastroenterol Hepatol. 2007 Apr; 4(4):175. PMID: 17404585.
      Citations:    Fields:    Translation:Humans
    299. Litcher-Kelly L, Kellerman Q, Hanauer SB, Stone AA. Feasibility and utility of an electronic diary to assess self-report symptoms in patients with inflammatory bowel disease. Ann Behav Med. 2007 Apr; 33(2):207-12. PMID: 17447873.
      Citations: 13     Fields:    Translation:Humans
    300. Hanauer SB. Balancing drug availability and patient safety. Nat Clin Pract Gastroenterol Hepatol. 2007 Mar; 4(3):117. PMID: 17339848.
      Citations:    Fields:    Translation:Humans
    301. Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, Bala M, Johanns J, Olson A, Hanauer SB. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007 Apr; 102(4):794-802. PMID: 17324131.
      Citations: 71     Fields:    Translation:Humans
    302. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007 Sep; 56(9):1232-9. PMID: 17299059; PMCID: PMC2701613.
      Citations: 286     Fields:    Translation:Humans
    303. Hanauer SB, Sandborn WJ. European evidence-based consensus on the diagnosis and management of Crohn's disease. Gut. 2007 Feb; 56(2):161-3. PMID: 17303600; PMCID: PMC1856750.
      Citations: 4     Fields:    Translation:Humans
    304. Hanauer SB. Stepping up to good health. Nat Clin Pract Gastroenterol Hepatol. 2007 Feb; 4(2):59. PMID: 17268538.
      Citations:    Fields:    Translation:Humans
    305. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007 Feb; 5(2):209-14. PMID: 17296529.
      Citations: 50     Fields:    Translation:Humans
    306. Hanauer SB. Fragile egos. Nat Clin Pract Gastroenterol Hepatol. 2007 Jan; 4(1):1. PMID: 17203077.
      Citations:    Fields:    Translation:Humans
    307. Hanauer SB, Sandborn WJ. Refining the role of TNF antagonists for Crohn's disease. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 1:S1-2. PMID: 17392632.
      Citations:    Fields:    Translation:Humans
    308. Hanauer SB. Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down". Rev Gastroenterol Disord. 2007; 7 Suppl 2:S17-22. PMID: 17392635.
      Citations: 8     Fields:    Translation:Humans
    309. Hanauer SB. The benefits of loperamide in the treatment of patients with IBS or IBD. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 3:S1-2. PMID: 18192960.
      Citations: 3     Fields:    Translation:Humans
    310. Shah SB, Hanauer SB. Treatment of diarrhea in patients with inflammatory bowel disease: concepts and cautions. Rev Gastroenterol Disord. 2007; 7 Suppl 3:S3-10. PMID: 18192964.
      Citations: 8     Fields:    Translation:HumansAnimals
    311. Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, Katz S, Goldblum R, Harrigan R, Hilton D, Hanauer SB. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007 Jan; 13(1):2-11. PMID: 17206633.
      Citations: 60     Fields:    Translation:Humans
    312. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Marteau P, Rutgeerts P, Sutherland LR, Lémann M, Schölmerich J. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb; 132(2):763-86. PMID: 17258735.
      Citations: 350     Fields:    Translation:Humans
    313. Kozuch PL, Hanauer SB. General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Dec; 35(4):757-73. PMID: 17129812.
      Citations: 8     Fields:    Translation:Humans
    314. Hanauer SB. A generic problem. Nat Clin Pract Gastroenterol Hepatol. 2006 Dec; 3(12):649. PMID: 17130869.
      Citations:    Fields:    
    315. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF, Colombel JF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan; 132(1):52-65. PMID: 17241859.
      Citations: 619     Fields:    Translation:HumansCTClinical Trials
    316. Schreiber S, Keshavarzian A, Isaacs KL, Schollenberger J, Guzman JP, Orlandi C, Hanauer SB. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology. 2007 Jan; 132(1):76-86. PMID: 17241861.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    317. Hanauer SB. Weighing in on obesity--a sample size issue? Nat Clin Pract Gastroenterol Hepatol. 2006 Nov; 3(11):593. PMID: 17068490.
      Citations:    Fields:    Translation:Humans
    318. Rubin DT, LoSavio A, Yadron N, Huo D, Hanauer SB. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006 Nov; 4(11):1346-50. PMID: 17059900.
      Citations: 35     Fields:    Translation:Humans
    319. Hanauer SB. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther. 2006 Oct; 24 Suppl 3:37-40. PMID: 16961743.
      Citations: 13     Fields:    Translation:Humans
    320. Hanauer SB. Fertile ground. Nat Clin Pract Gastroenterol Hepatol. 2006 Oct; 3(10):533. PMID: 17008918.
      Citations:    Fields:    Translation:Humans
    321. Hanauer SB. "Hit me with your best shot... Fire away!". Nat Clin Pract Gastroenterol Hepatol. 2006 Sep; 3(9):473. PMID: 16951659.
      Citations:    Fields:    Translation:Humans
    322. Hanauer SB. Safety first: messages from Digestive Disease Week 2006. Nat Clin Pract Gastroenterol Hepatol. 2006 Aug; 3(8):415. PMID: 16883326.
      Citations:    Fields:    Translation:Humans
    323. Hanauer SB. It's right under our nose: homage to the Nobel Prize and other stories! Nat Clin Pract Gastroenterol Hepatol. 2006 Jul; 3(7):355. PMID: 16819477.
      Citations:    Fields:    Translation:HumansCells
    324. Sands BE, Sandborn WJ, Wolf DC, Katz S, Safdi M, Schwartz DA, Hanauer SB. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol. 2006 Jul; 40(6):482-9. PMID: 16825929.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    325. Hanauer SB. Steroids as recreational drugs. Nat Clin Pract Gastroenterol Hepatol. 2006 Jun; 3(6):295. PMID: 16741529.
      Citations:    Fields:    Translation:Humans
    326. Hanauer SB. New lessons: classic treatments, expanding options in ulcerative colitis. Colorectal Dis. 2006 May; 8 Suppl 1:20-4. PMID: 16594960.
      Citations: 3     Fields:    Translation:Humans
    327. Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006 May; 101(5):1030-8. PMID: 16606351.
      Citations: 67     Fields:    Translation:Humans
    328. Nguyen GC, Torres EA, Regueiro M, Bromfield G, Bitton A, Stempak J, Dassopoulos T, Schumm P, Gregory FJ, Griffiths AM, Hanauer SB, Hanson J, Harris ML, Kane SV, Orkwis HK, Lahaie R, Oliva-Hemker M, Pare P, Wild GE, Rioux JD, Yang H, Duerr RH, Cho JH, Steinhart AH, Brant SR, Silverberg MS. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006 May; 101(5):1012-23. PMID: 16696785.
      Citations: 109     Fields:    Translation:Humans
    329. Hanauer SB, Schölmerich J. Evidence-based medicine: applied science? Nat Clin Pract Gastroenterol Hepatol. 2006 Apr; 3(4):177. PMID: 16582938.
      Citations:    Fields:    Translation:Humans
    330. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006 Mar; 63(3):433-42; quiz 464. PMID: 16500392.
      Citations: 132     Fields:    Translation:Humans
    331. Hanauer SB. Procreation without recreation. Nat Clin Pract Gastroenterol Hepatol. 2006 Mar; 3(3):117. PMID: 16511528.
      Citations:    Fields:    Translation:Humans
    332. Achkar JP, Dassopoulos T, Silverberg MS, Tuvlin JA, Duerr RH, Brant SR, Siminovitch K, Reddy D, Datta LW, Bayless TM, Zhang L, Barmada MM, Rioux JD, Steinhart AH, McLeod RS, Griffiths AM, Cohen Z, Yang H, Bromfield GP, Schumm P, Hanauer SB, Cho JH, Nicolae DL. Phenotype-stratified genetic linkage study demonstrates that IBD2 is an extensive ulcerative colitis locus. Am J Gastroenterol. 2006 Mar; 101(3):572-80. PMID: 16542294.
      Citations: 7     Fields:    Translation:Humans
    333. Hanauer SB. The 'tipping point' applied. Nat Clin Pract Gastroenterol Hepatol. 2006 Feb; 3(2):59. PMID: 16456553.
      Citations: 1     Fields:    Translation:Humans
    334. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb; 130(2):323-33; quiz 591. PMID: 16472588.
      Citations: 456     Fields:    Translation:Humans
    335. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006 Jan; 12 Suppl 1:S3-9. PMID: 16378007.
      Citations: 331     Fields:    Translation:HumansAnimals
    336. Hanauer SB, Sandborn WJ, Vakil N, Katz PO, Talley NJ, Rex DK, Hawes RH, Guda NM, Freeman ML, Keeffe EB, Balart LA. Best of DDW 2006. Rev Gastroenterol Disord. 2006; 6(3):153-89. PMID: 16957658.
      Citations:    Fields:    Translation:Humans
    337. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 08; 353(23):2462-76. PMID: 16339095.
      Citations: 1198     Fields:    Translation:Humans
    338. Hanauer SB. I've sold my sport-utility vehicle. Nat Clin Pract Gastroenterol Hepatol. 2005 Dec; 2(12):551. PMID: 16327816.
      Citations: 1     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    339. Sandborn WJ, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P, International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group, Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group, Colombel JF. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005 Nov 03; 353(18):1912-25. PMID: 16267322.
      Citations: 255     Fields:    Translation:HumansCellsCTClinical Trials
    340. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005 Nov; 100(11):2478-85. PMID: 16279903.
      Citations: 78     Fields:    Translation:Humans
    341. Sands BE, Abreu MT, Ferry GD, Griffiths AM, Hanauer SB, Isaacs KL, Lewis JD, Sandborn WJ, Steinhart AH. Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis. 2005 Nov; 11 Suppl 1:S22-8. PMID: 16254479.
      Citations: 8     Fields:    Translation:Humans
    342. Hanauer SB. Top-down versus step-up approaches to chronic inflammatory bowel disease: presumed innocent or presumed guilty. Nat Clin Pract Gastroenterol Hepatol. 2005 Nov; 2(11):493. PMID: 16355136.
      Citations: 9     Fields:    Translation:Humans
    343. Hanauer SB. Another one bites the dust. Nat Clin Pract Gastroenterol Hepatol. 2005 Oct; 2(10):435. PMID: 16224457.
      Citations:    Fields:    Translation:Humans
    344. Hanauer SB. Infliximab or cyclosporine for severe ulcerative colitis. Gastroenterology. 2005 Oct; 129(4):1358-9; author reply 1359. PMID: 16230092.
      Citations:    Fields:    Translation:Humans
    345. Sparrow MP, Hande SA, Friedman S, Lim WC, Reddy SI, Cao D, Hanauer SB. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 2005 Sep 01; 22(5):441-6. PMID: 16128682.
      Citations: 58     Fields:    Translation:Humans
    346. Hanauer SB. Supplemental evidence. Nat Clin Pract Gastroenterol Hepatol. 2005 Sep; 2(9):375. PMID: 16265405.
      Citations:    Fields:    Translation:Humans
    347. Hanauer SB. Novel potential perils of volunteering for clinical trials. Nat Clin Pract Gastroenterol Hepatol. 2005 Aug; 2(8):337. PMID: 16265383.
      Citations:    Fields:    Translation:Humans
    348. Sandborn WJ, Feagan BG, Hanauer SB, Campieri M, Greenberg GR, Löfberg R. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005 Aug; 100(8):1780-7. PMID: 16086715.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    349. Hanauer SB. Institutional review boards: the cost to academic medical centers. Nat Clin Pract Gastroenterol Hepatol. 2005 Jul; 2(7):287. PMID: 16265262.
      Citations: 1     Fields:    Translation:Humans
    350. Lim WC, Hanauer SB, Li YC. Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Jul; 2(7):308-15. PMID: 16265284.
      Citations: 83     Fields:    Translation:HumansAnimalsCells
    351. Hanauer SB. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease. Am J Gastroenterol. 2005 Jul; 100(7):1438-9. PMID: 15984961.
      Citations:    Fields:    Translation:Humans
    352. Hanauer SB. The case for using 5-aminosalicyclates in Crohn's disease: pro. Inflamm Bowel Dis. 2005 Jun; 11(6):609-12. PMID: 15905710.
      Citations: 3     Fields:    Translation:Humans
    353. Hanauer SB, Thisted RA. Treatment of Crohn's disease: the "long" of it. Gastroenterology. 2005 Jun; 128(7):2164-6. PMID: 15940649.
      Citations: 2     Fields:    Translation:Humans
    354. Hanauer SB. Obesity and visceral fat: a growing inflammatory disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Jun; 2(6):245. PMID: 16265208.
      Citations: 3     Fields:    Translation:Humans
    355. Ross AS, Gasparaitis A, Hurst R, Hanauer SB, Rubin DT. Superior mesenteric vein thrombosis after colectomy in a patient with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Jun; 2(6):281-5; quiz 1 p following 285. PMID: 16265232.
      Citations: 3     Fields:    Translation:Humans
    356. Hanauer SB. Assessment, prevention and treatment of osteoporosis in inflammatory bowel disease patients: a bone of contention. Nat Clin Pract Gastroenterol Hepatol. 2005 May; 2(5):199. PMID: 16265185.
      Citations:    Fields:    Translation:Humans
    357. Feagan BG, Bala M, Yan S, Olson A, Hanauer S. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol. 2005 May-Jun; 39(5):390-5. PMID: 15815207.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    358. Hanauer SB. The 'upside' of travelers' diarrhea: a personal case report. Nat Clin Pract Gastroenterol Hepatol. 2005 Apr; 2(4):161. PMID: 16265160.
      Citations: 2     Fields:    Translation:Humans
    359. Kles KA, Vavricka SR, Turner JR, Musch MW, Hanauer SB, Chang EB. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum. Inflamm Bowel Dis. 2005 Mar; 11(3):253-7. PMID: 15735431.
      Citations: 5     Fields:    Translation:Animals
    360. Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):363-71. PMID: 15709986.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    361. Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):373-84. PMID: 15709987.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    362. Hanauer SB. The whole is greater than the sum. Nat Clin Pract Gastroenterol Hepatol. 2005 Feb; 2(2):59. PMID: 16265102.
      Citations:    Fields:    Translation:Humans
    363. Hanauer SB. Conflicts of interest. Nat Clin Pract Gastroenterol Hepatol. 2005 Jan; 2(1):1. PMID: 16265074.
      Citations:    Fields:    Translation:Humans
    364. Harrell LE, Rubin DT, Hanauer SB. Fever and right upper quadrant pain in a pregnant woman at 30 weeks' gestation. Nat Clin Pract Gastroenterol Hepatol. 2004 Dec; 1(2):113-6; quiz 1 p following 116. PMID: 16265073.
      Citations: 1     Fields:    Translation:Humans
    365. Hanauer SB, Solomon J. Should you "just say 'no'"? Nat Clin Pract Gastroenterol Hepatol. 2004 Dec; 1(2):59. PMID: 16265046.
      Citations:    Fields:    Translation:Humans
    366. Hanauer SB. Update on the etiology, pathogenesis and diagnosis of ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2004 Nov; 1(1):26-31. PMID: 16265041.
      Citations: 9     Fields:    Translation:Humans
    367. Hanauer SB, Sparrow M. COLAL-PRED Alizyme. Curr Opin Investig Drugs. 2004 Nov; 5(11):1192-7. PMID: 15573870.
      Citations: 1     Fields:    Translation:HumansAnimals
    368. Sandborn WJ, Hanauer S, Loftus EV, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004 Oct; 99(10):1984-9. PMID: 15447761.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    369. Hanauer SB. Review article: aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2004 Oct; 20 Suppl 4:60-5. PMID: 15352896.
      Citations: 17     Fields:    Translation:Humans
    370. Hanauer SB. Review article: the long-term management of ulcerative colitis. Aliment Pharmacol Ther. 2004 Oct; 20 Suppl 4:97-101. PMID: 15352903.
      Citations: 6     Fields:    Translation:Humans
    371. Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, Present DH. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004 Sep; 127(3):723-9. PMID: 15362027.
      Citations: 104     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    372. Kane S, Kisiel J, Shih L, Hanauer S. HLA disparity determines disease activity through pregnancy in women with inflammatory bowel disease. Am J Gastroenterol. 2004 Aug; 99(8):1523-6. PMID: 15307871.
      Citations: 13     Fields:    Translation:Humans
    373. Lichtenstein GR, Hanauer SB, Kane SV, Present DH. Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease. Inflamm Bowel Dis. 2004 Jul; 10 Suppl 2:S2-10. PMID: 15475770.
      Citations: 4     Fields:    Translation:Humans
    374. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, Rutgeerts P. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004 Jul; 2(7):542-53. PMID: 15224278.
      Citations: 144     Fields:    Translation:HumansCTClinical Trials
    375. Lichtenstein GR, Cuffari C, Kane SV, Hanauer S, Present DH. Maintaining remissions across the lifespan: a roundtable discussion with Crohn's disease experts. Inflamm Bowel Dis. 2004 Jul; 10 Suppl 2:S11-21. PMID: 15475769.
      Citations: 1     Fields:    Translation:Humans
    376. Hanauer SB, Sparrow M. Therapy of ulcerative colitis. Curr Opin Gastroenterol. 2004 Jul; 20(4):345-50. PMID: 15703663.
      Citations: 5     Fields:    
    377. Harrell LE, Hanauer SB. Mesalamine derivatives in the treatment of Crohn's disease. Gastroenterol Clin North Am. 2004 Jun; 33(2):303-17, ix-x. PMID: 15177540.
      Citations: 8     Fields:    Translation:Humans
    378. Sandborn WJ, Hanauer SB, Buch A. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Aliment Pharmacol Ther. 2004 May 15; 19(10):1089-98. PMID: 15142198.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    379. Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology. 2004 May; 126(6):1582-92. PMID: 15168369.
      Citations: 41     Fields:    Translation:Humans
    380. Hanauer SB, Strömberg U. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004 May; 2(5):379-88. PMID: 15118975.
      Citations: 52     Fields:    Translation:Humans
    381. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004 Feb; 126(2):402-13. PMID: 14762776.
      Citations: 208     Fields:    Translation:HumansCTClinical Trials
    382. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004 Jan; 99(1):91-6. PMID: 14687148.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    383. Lim WC, Hanauer SB. Controversies with aminosalicylates in inflammatory bowel disease. Rev Gastroenterol Disord. 2004; 4(3):104-17. PMID: 15359211.
      Citations: 6     Fields:    Translation:Humans
    384. Hanauer SB. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies. Rev Gastroenterol Disord. 2004; 4 Suppl 3:S18-24. PMID: 15580149.
      Citations: 12     Fields:    Translation:Humans
    385. Lim WC, Hanauer SB. Emerging biologic therapies in inflammatory bowel disease. Rev Gastroenterol Disord. 2004; 4(2):66-85. PMID: 15184826.
      Citations: 11     Fields:    Translation:Humans
    386. Hanauer SB. Factoring in growth factors for treatment of inflammatory bowel disease. Curr Gastroenterol Rep. 2003 Dec; 5(6):485. PMID: 14602056.
      Citations:    Fields:    
    387. Hanauer SB. Factoring in growth factors II. Curr Gastroenterol Rep. 2003 Dec; 5(6):486. PMID: 14602057.
      Citations:    Fields:    
    388. Navarro F, Hanauer SB. Treatment of inflammatory bowel disease: safety and tolerability issues. Am J Gastroenterol. 2003 Dec; 98(12 Suppl):S18-23. PMID: 14697914.
      Citations: 9     Fields:    Translation:Humans
    389. Chi KD, Hanauer SB. Benign solitary cecal ulcer: a case report and review of the literature. Dig Dis Sci. 2003 Nov; 48(11):2207-12. PMID: 14705829.
      Citations: 9     Fields:    Translation:Humans
    390. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB, American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003 Nov; 125(5):1508-30. PMID: 14598268.
      Citations: 159     Fields:    Translation:Humans
    391. Brant SR, Picco MF, Achkar JP, Bayless TM, Kane SV, Brzezinski A, Nouvet FJ, Bonen D, Karban A, Dassopoulos T, Karaliukas R, Beaty TH, Hanauer SB, Duerr RH, Cho JH. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm Bowel Dis. 2003 Sep; 9(5):281-9. PMID: 14555911.
      Citations: 67     Fields:    Translation:Humans
    392. Laine L, Hanauer SB. Considerations in the management of steroid-dependent Crohn's disease. Gastroenterology. 2003 Sep; 125(3):906-10. PMID: 12949734.
      Citations: 2     Fields:    Translation:Humans
    393. Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J, Martin C, Sandler RS. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003 Aug; 125(2):380-8. PMID: 12891539.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    394. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003 Jun; 98(6):1309-14. PMID: 12818275.
      Citations: 114     Fields:    Translation:Humans
    395. Sandborn WJ, Sands BE, Wolf DC, Valentine JF, Safdi M, Katz S, Isaacs KL, Wruble LD, Katz J, Present DH, Loftus EV, Graeme-Cook F, Odenheimer DJ, Hanauer SB. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther. 2003 Jun 01; 17(11):1355-64. PMID: 12786629.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    396. Hanauer SB. Immunogenicity of infliximab in Crohn's disease. N Engl J Med. 2003 May 22; 348(21):2155-6; author reply 2155-6. PMID: 12761378.
      Citations: 3     Fields:    Translation:Humans
    397. Klapman JB, Ene-Stroescu D, Becker MA, Hanauer SB. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis. 2003 May; 9(3):176-8. PMID: 12792223.
      Citations: 8     Fields:    Translation:Humans
    398. Hanauer SB. Treatment of ulcerative colitis with balsalazide: response to Drs Johnson, Green, and Pruitt. Am J Gastroenterol. 2003 Mar; 98(3):697-8. PMID: 12650813.
      Citations: 1     Fields:    Translation:Humans
    399. Hanauer SB. Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol. 2003 Feb; 17(1):131-7. PMID: 12617888.
      Citations: 16     Fields:    Translation:HumansPHPublic Health
    400. Hanauer SB. Assessing the risk of lymphomas in inflammatory bowel disease. Rev Gastroenterol Disord. 2003; 3(1):50-1. PMID: 12684594.
      Citations:    Fields:    
    401. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003 Jan; 17(1):29-42. PMID: 12492730.
      Citations: 53     Fields:    Translation:Humans
    402. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 2003; 3(2):81-92. PMID: 12776005.
      Citations: 44     Fields:    Translation:Humans
    403. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003 Jan; 114(1):39-43. PMID: 12543288.
      Citations: 163     Fields:    Translation:Humans
    404. Hanauer SB. Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis. Am J Gastroenterol. 2003 Jan; 98(1):215-6. PMID: 12526968.
      Citations: 1     Fields:    Translation:Humans
    405. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002 Dec; 97(12):2962-72. PMID: 12492177.
      Citations: 51     Fields:    Translation:Humans
    406. Duerr RH, Barmada MM, Zhang L, Achkar JP, Cho JH, Hanauer SB, Brant SR, Bayless TM, Baldassano RN, Weeks DE. Evidence for an inflammatory bowel disease locus on chromosome 3p26: linkage, transmission/disequilibrium and partitioning of linkage. Hum Mol Genet. 2002 Oct 01; 11(21):2599-606. PMID: 12354785.
      Citations: 10     Fields:    Translation:HumansCells
    407. Hanauer SB. New steroids for IBD: progress report. Gut. 2002 Aug; 51(2):182-3. PMID: 12117876; PMCID: PMC1773302.
      Citations: 10     Fields:    Translation:Humans
    408. Tremaine WJ, Hanauer SB, Katz S, Winston BD, Levine JG, Persson T, Persson A, Budesonide CIR United States Study Group. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol. 2002 Jul; 97(7):1748-54. PMID: 12135030.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    409. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002 May 04; 359(9317):1541-9. PMID: 12047962.
      Citations: 1079     Fields:    Translation:HumansCTClinical Trials
    410. Harrison J, Hanauer SB. Medical treatment of Crohn's disease. Gastroenterol Clin North Am. 2002 Mar; 31(1):167-84, x. PMID: 12122730.
      Citations: 1     Fields:    Translation:Humans
    411. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Modigliani R, Present DH, Rutgeerts P, Stange EF, Sutherland LR, Löfberg R, Schölmerich J. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002 Feb; 122(2):512-30. PMID: 11832465.
      Citations: 181     Fields:    Translation:Humans
    412. Vakil N, Hawes RH, Hanauer SB, Freeman ML, Camilleri M. Best of DDW 2002. Highlights from the 2002 Digestive Disease Week. May 19-22, 2002, San Francisco, CA. Rev Gastroenterol Disord. 2002; 2(3):126-41. PMID: 12227216.
      Citations:    Fields:    Translation:Humans
    413. Tytgat GN, Van Nueten L, Van De Velde I, Joslyn A, Hanauer SB. Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. Aliment Pharmacol Ther. 2002 Jan; 16(1):87-99. PMID: 11856082.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    414. Baron BW, Jeon HR, Glunz C, Peterson A, Cohen R, Hanauer S, Rubin D, Hart J, Baron JM. First two patients with ulcerative colitis who developed classical thrombotic thrombocytopenic purpura successfully treated with medical therapy and plasma exchange. J Clin Apher. 2002; 17(4):204-6. PMID: 12494414.
      Citations: 2     Fields:    Translation:Humans
    415. Hanauer SB. Can cyclosporine go it alone in severe ulcerative colitis? Curr Gastroenterol Rep. 2001 Dec; 3(6):455-6. PMID: 11696281.
      Citations: 4     Fields:    Translation:Humans
    416. Hanauer SB. The smoke is clearing in Crohn's disease. Curr Gastroenterol Rep. 2001 Dec; 3(6):456-7. PMID: 12953718.
      Citations:    Fields:    Translation:Humans
    417. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001 Nov; 121(5):1088-94. PMID: 11677200.
      Citations: 205     Fields:    Translation:HumansCTClinical Trials
    418. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001 Oct; 96(10):2929-33. PMID: 11693328.
      Citations: 109     Fields:    Translation:Humans
    419. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Cho JH, Nuñez G. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001 May 31; 411(6837):603-6. PMID: 11385577.
      Citations: 1513     Fields:    Translation:HumansCells
    420. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR, CDP571 Crohn's Disease Study Group. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001 May; 120(6):1330-8. PMID: 11313302.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    421. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001 May; 7(2):83-8. PMID: 11383595.
      Citations: 106     Fields:    Translation:HumansCTClinical Trials
    422. Hanauer SB. Crohn's disease therapy: step up or top down therapy. Acta Gastroenterol Belg. 2001 Apr-Jun; 64(2):189-90. PMID: 11475132.
      Citations:    Fields:    Translation:Humans
    423. Hanauer SB. Biologics in peri-operative management of Crohn's disease. Acta Gastroenterol Belg. 2001 Apr-Jun; 64(2):191-2. PMID: 11475133.
      Citations: 1     Fields:    Translation:Humans
    424. Ellman MH, Hanauer S, Sitrin M, Cohen R. Crohn's disease arthritis treated with infliximab: an open trial in four patients. J Clin Rheumatol. 2001 Apr; 7(2):67-71. PMID: 17039097.
      Citations: 12     Fields:    
    425. Hanauer SB, Sandborn W, Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2001 Mar; 96(3):635-43. PMID: 11280528.
      Citations: 81     Fields:    Translation:Humans
    426. Freeman ML, Hawes RH, Vakil N, Camilleri M, Hanauer SB. Best of DDW 2001. Highlights from the 2001 Digestive Disease Week. May 20-23, 2001, Atlanta, GA. Rev Gastroenterol Disord. 2001; 1(2):100-10. PMID: 12120175.
      Citations:    Fields:    Translation:Humans
    427. Hanauer SB, Dassopoulos T. Evolving treatment strategies for inflammatory bowel disease. Annu Rev Med. 2001; 52:299-318. PMID: 11160781.
      Citations: 8     Fields:    Translation:Humans
    428. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther. 2001 Jan; 15(1):35-44. PMID: 11136276.
      Citations: 14     Fields:    Translation:Humans
    429. Hanauer SB. Update on medical management of inflammatory bowel disease: ulcerative colitis. Rev Gastroenterol Disord. 2001; 1(4):169-76. PMID: 12120183.
      Citations: 3     Fields:    Translation:Humans
    430. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol. 2000 Dec; 95(12):3469-77. PMID: 11151879.
      Citations: 33     Fields:    Translation:Humans
    431. Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, Jacyna M, Lashner BA, Gangl A, Rutgeerts P, Isaacs K, van Deventer SJ, Koningsberger JC, Cohard M, LeBeaut A, Hanauer SB, Schreiber S. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology. 2000 Dec; 119(6):1461-72. PMID: 11113067.
      Citations: 129     Fields:    Translation:HumansCTClinical Trials
    432. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, Hanauer SB, Kilian A, Cohard M, LeBeaut A, Feagan B. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology. 2000 Dec; 119(6):1473-82. PMID: 11113068.
      Citations: 130     Fields:    Translation:HumansCTClinical Trials
    433. Brant SR, Panhuysen CI, Bailey-Wilson JE, Rohal PM, Lee S, Mann J, Ravenhill G, Kirschner BS, Hanauer SB, Cho JH, Bayless TM. Linkage heterogeneity for the IBD1 locus in Crohn's disease pedigrees by disease onset and severity. Gastroenterology. 2000 Dec; 119(6):1483-90. PMID: 11113069.
      Citations: 16     Fields:    Translation:HumansCells
    434. Hanauer SB. Maintenance therapies for Crohn's disease: steroid dependence and delaying postoperative recurrence. Curr Gastroenterol Rep. 2000 Dec; 2(6):433. PMID: 11079042.
      Citations: 1     Fields:    
    435. Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000 Nov; 23(5):429-48. PMID: 11085348.
      Citations: 42     Fields:    Translation:Humans
    436. Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000 Nov; 95(11):3150-6. PMID: 11095334.
      Citations: 21     Fields:    Translation:Humans
    437. Michelassi F, Hurst RD, Melis M, Rubin M, Cohen R, Gasparitis A, Hanauer SB, Hart J. Side-to-side isoperistaltic strictureplasty in extensive Crohn's disease: a prospective longitudinal study. Ann Surg. 2000 Sep; 232(3):401-8. PMID: 10973390; PMCID: PMC1421153.
      Citations: 22     Fields:    Translation:Humans
    438. Rubin DT, Hanauer SB. Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000 Aug; 12(8):855-62. PMID: 10958212.
      Citations: 34     Translation:Humans
    439. Hanauer S, Good LI, Goodman MW, Pizinger RJ, Strum WB, Lyss C, Haber G, Williams CN, Robinson M. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol. 2000 Jul; 95(7):1749-54. PMID: 10925979.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    440. Hanauer SB. Medical therapy for ulcerative colitis. Curr Opin Gastroenterol. 2000 Jul; 16(4):324-8. PMID: 17031096.
      Citations: 3     Fields:    
    441. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med. 2000 Jun 01; 342(22):1627-32. PMID: 10833208.
      Citations: 146     Fields:    Translation:HumansCTClinical Trials
    442. Cho JH, Nicolae DL, Ramos R, Fields CT, Rabenau K, Corradino S, Brant SR, Espinosa R, LeBeau M, Hanauer SB, Bodzin J, Bonen DK. Linkage and linkage disequilibrium in chromosome band 1p36 in American Chaldeans with inflammatory bowel disease. Hum Mol Genet. 2000 May 22; 9(9):1425-32. PMID: 10814724.
      Citations: 16     Fields:    Translation:HumansCells
    443. Achkar JP, Hanauer SB. Medical therapy to reduce postoperative Crohn's disease recurrence. Am J Gastroenterol. 2000 May; 95(5):1139-46. PMID: 10811318.
      Citations: 9     Fields:    Translation:Humans
    444. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000 May; 95(5):1263-76. PMID: 10811338.
      Citations: 51     Fields:    Translation:Humans
    445. Hanauer SB. Surveying surveillance: are gastroenterologists consistently inconsistent, inconsistently consistent, or poorly educated? Gastrointest Endosc. 2000 Feb; 51(2):240-2. PMID: 10650283.
      Citations:    Fields:    Translation:Humans
    446. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000 Feb; 6(1):8-15. PMID: 10701144.
      Citations: 289     Fields:    Translation:Humans
    447. Hanauer SB. Evolutionary biologic therapy for inflammatory bowel disease. Curr Gastroenterol Rep. 1999 Dec; 1(6):467-9. PMID: 10980987.
      Citations:    Fields:    Translation:Humans
    448. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999 Dec; 117(6):1271-7. PMID: 10579967.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    449. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999 Oct; 117(4):761-9. PMID: 10500056.
      Citations: 185     Fields:    Translation:HumansCTClinical Trials
    450. Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, Hanauer SB, McDonald JW, Feagan BG, Fedorak RN, Isaacs KL, Pike MG, Mays DC, Lipsky JJ, Gordon S, Kleoudis CS, Murdock RH. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology. 1999 Sep; 117(3):527-35. PMID: 10464128.
      Citations: 39     Fields:    Translation:HumansCellsCTClinical Trials
    451. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999 Sep; 13 Suppl 4:16-22; discussion 38. PMID: 10597335.
      Citations: 38     Fields:    Translation:Humans
    452. Hanauer SB. Updating the approach to Crohn's disease. Hosp Pract (1995). 1999 Aug 15; 34(8):77-8, 81-3, 87-93; discussion 94. PMID: 10459364.
      Citations: 1     Fields:    Translation:Humans
    453. Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW, Miner PB, Safdi MA, Galandiuk S, Hanauer SB, Varilek GW, Buchman AL, Rodgers VD, Salzberg B, Cai B, Loewy J, DeBruin MF, Rogge H, Shapiro M, Schwertschlag US. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology. 1999 Jul; 117(1):58-64. PMID: 10381910.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    454. Hanauer SB. Medical therapy for Crohn's disease. Curr Opin Gastroenterol. 1999 Jul; 15(4):308-14. PMID: 17023963.
      Citations: 4     Fields:    
    455. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999 Jun; 94(6):1587-92. PMID: 10364029.
      Citations: 68     Fields:    Translation:Humans
    456. Stein RB, Hanauer SB. Medical therapy for inflammatory bowel disease. Gastroenterol Clin North Am. 1999 Jun; 28(2):297-321. PMID: 10372270.
      Citations: 19     Fields:    Translation:Humans
    457. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 06; 340(18):1398-405. PMID: 10228190.
      Citations: 565     Fields:    Translation:HumansCTClinical Trials
    458. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May; 5(2):119-33. PMID: 10338381.
      Citations: 98     Fields:    Translation:Humans
    459. Hanauer SB. Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis. Gut. 1999 Apr; 44(4):455. PMID: 10075949; PMCID: PMC1727455.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    460. Cohen RD, Brodsky AL, Hanauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis. 1999 Feb; 5(1):1-10. PMID: 10028443.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    461. Hanauer SB. No butts about it: put the fire out by lighting up. Inflamm Bowel Dis. 1998 Nov; 4(4):326; discussion 327. PMID: 9836087.
      Citations:    Fields:    Translation:Humans
    462. Brant SR, Fu Y, Fields CT, Baltazar R, Ravenhill G, Pickles MR, Rohal PM, Mann J, Kirschner BS, Jabs EW, Bayless TM, Hanauer SB, Cho JH. American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12. Gastroenterology. 1998 Nov; 115(5):1056-61. PMID: 9797357.
      Citations: 26     Fields:    Translation:HumansCells
    463. Kane SV, Sable K, Hanauer SB. The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol. 1998 Oct; 93(10):1867-72. PMID: 9772046.
      Citations: 58     Fields:    Translation:Humans
    464. Hanauer SB, Cohen RD, Becker RV, Larson LR, Vreeland MG. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther. 1998 Sep-Oct; 20(5):1009-28. PMID: 9829451.
      Citations: 9     Fields:    Translation:Humans
    465. Winter AM, Koeppen H, Hanauer SB. Non-Hodgkin's lymphoma presenting nine years after ileal-pouch ileoanal anastomosis for ulcerative colitis. Am J Gastroenterol. 1998 Sep; 93(9):1589-90. PMID: 9732957.
      Citations: 1     Fields:    Translation:Humans
    466. Hanauer SB, Robinson M, Pruitt R, Lazenby AJ, Persson T, Nilsson LG, Walton-Bowen K, Haskell LP, Levine JG. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology. 1998 Sep; 115(3):525-32. PMID: 9721148.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    467. Cho JH, Nicolae DL, Gold LH, Fields CT, LaBuda MC, Rohal PM, Pickles MR, Qin L, Fu Y, Mann JS, Kirschner BS, Jabs EW, Weber J, Hanauer SB, Bayless TM, Brant SR. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci U S A. 1998 Jun 23; 95(13):7502-7. PMID: 9636179; PMCID: PMC22666.
      Citations: 84     Fields:    Translation:HumansCells
    468. Stein RB, Hanauer SB. Medical management of Crohn's disease. Drugs Today (Barc). 1998 Jun; 34(6):541-8. PMID: 15010715.
      Citations: 1     Fields:    
    469. Hanauer SB. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. Inflamm Bowel Dis. 1998 May; 4(2):79-83. PMID: 9589293.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    470. Hanauer SB. How do I treat erythema nodosum, aphthous ulcerations, and pyoderma gangrenosum? Inflamm Bowel Dis. 1998 Feb; 4(1):70; discussion 73. PMID: 9552231.
      Citations:    Fields:    Translation:Humans
    471. Winter AM, Hanauer SB. Medical management of perianal Crohn's disease. Semin Gastrointest Dis. 1998 Jan; 9(1):10-4. PMID: 9547851.
      Citations:    Fields:    Translation:Humans
    472. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997 Oct 09; 337(15):1029-35. PMID: 9321530.
      Citations: 683     Fields:    Translation:HumansCTClinical Trials
    473. Kornbluth A, Present DH, Lichtiger S, Hanauer S. Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol. 1997 Sep; 92(9):1424-8. PMID: 9317057.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    474. Breuer RI, Soergel KH, Lashner BA, Christ ML, Hanauer SB, Vanagunas A, Harig JM, Keshavarzian A, Robinson M, Sellin JH, Weinberg D, Vidican DE, Flemal KL, Rademaker AW. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut. 1997 Apr; 40(4):485-91. PMID: 9176076; PMCID: PMC1027123.
      Citations: 75     Fields:    Translation:HumansCTClinical Trials
    475. Hanauer SB, Meyers S. Management of Crohn's disease in adults. Am J Gastroenterol. 1997 Apr; 92(4):559-66. PMID: 9128300.
      Citations: 19     Fields:    Translation:Humans
    476. Roberts WG, Simon TJ, Berlin RG, Haggitt RC, Snyder ES, Stenson WF, Hanauer SB, Reagan JE, Cagliola A, Tanaka WK, Simon S, Berger ML. Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology. 1997 Mar; 112(3):725-32. PMID: 9041233.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    477. Cho JH, Fu Y, Kirschner BS, Hanauer SB. Confirmation of a susceptibility locus for Crohn's disease on chromosome 16. Inflamm Bowel Dis. 1997; 3(3):186-90. PMID: 23282803.
      Citations: 5     Fields:    
    478. D'haens G, Baert F, Gasparaitis A, Hanauer S. Length and type of recurrent ileitis after ileal resection correlate with presurgical features in Crohn's disease. Inflamm Bowel Dis. 1997; 3(4):249-53. PMID: 23282870.
      Citations:    Fields:    
    479. Sutherland LR, Hanauer S, Scholmerich J, Task Force on Clinical Trials of the International Organisation for the Study of Inflammatory Bowel . Standards for trials of therapy in inflammatory bowel disease. Inflamm Bowel Dis. 1997; 3(4):277-83. PMID: 23282874.
      Citations: 1     Fields:    
    480. Anderson R, Kaariainen IT, Hanauer SB. Protein-losing enteropathy and massive pulmonary embolism in a patient with giant inflammatory polyposis and quiescent ulcerative colitis. Am J Med. 1996 Sep; 101(3):323-5. PMID: 8873495.
      Citations: 8     Fields:    Translation:Humans
    481. Schlager SI, Hanauer SB. New Therapeutic Approaches to Peptic Ulcer Disease: The Role of Helicobacter Pylori. Am J Ther. 1996 Aug; 3(8):586-596. PMID: 11862295.
      Citations:    Fields:    
    482. Roman-Unfer S, Bitran JD, Garrison L, Proeschel C, Hanauer S, Schroeder L, Johnson L, Klein L, Martinec J. A phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood hematopoietic progenitor cells. Exp Hematol. 1996 Jun; 24(7):823-8. PMID: 8647233.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    483. Hanauer SB. pANCA and classification resistance in ulcerative colitis. Mayo Clin Proc. 1996 May; 71(5):517-8. PMID: 8628035.
      Citations:    Fields:    Translation:Humans
    484. Cohen RD, Hanauer SB. Protection from primary sclerosing cholangitis: smoke trails of just coattails? Gastroenterology. 1996 May; 110(5):1658-62. PMID: 8613079.
      Citations: 2     Fields:    Translation:Humans
    485. Purl S, Johnson L, Hanauer S, Schroeder L, Proeschel C, Alberts J. Diphenhydramine provides relief of cyclophosphamide-related symptoms. Oncol Nurs Forum. 1996 Apr; 23(3):542. PMID: 8801517.
      Citations:    Fields:    Translation:Humans
    486. Hanauer SB. Inflammatory bowel disease. N Engl J Med. 1996 Mar 28; 334(13):841-8. PMID: 8596552.
      Citations: 101     Fields:    Translation:Humans
    487. Bitran JD, Samuels B, Klein L, Hanauer S, Johnson L, Martinec J, Harris E, Kempler J, White W. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant. 1996 Feb; 17(2):157-62. PMID: 8640160.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    488. Elton E, Hanauer SB. Review article: the medical management of Crohn's disease. Aliment Pharmacol Ther. 1996 Feb; 10(1):1-22. PMID: 8871440.
      Citations: 3     Fields:    Translation:Humans
    489. Hanauer SB. Treatment of perianal Crohn's disease: a medical approach. Inflamm Bowel Dis. 1996; 2(1):64-6. PMID: 23282457.
      Citations:    Fields:    
    490. Hanauer SB, Sutherland L. Little patients: big issues. Inflamm Bowel Dis. 1996; 2(2):121. PMID: 23282519.
      Citations:    Fields:    
    491. Present DH, Murphy LK, Hanauer SB. Challenges in IBD Research: The Clinical Research Agenda. Inflamm Bowel Dis. 1996; 2(3):189-99. PMID: 23282564.
      Citations:    Fields:    
    492. Campieri M, Gilat T, Hanauer S, Korelitz B, Lauritsen K, Malchow H, Martin F, Miglioli M, Modigliani R, Present D, Sutherland L, Schölmerich J. Drug Trials in Inflammatory Bowel Diseases 1993-1995: A Survey Conducted by the IOIBD. Inflamm Bowel Dis. 1996; 2(4):265-7. PMID: 23282593.
      Citations:    Fields:    
    493. Sutherland LR, Hanauer SB. A registry of clinical trials. Inflamm Bowel Dis. 1996; 2(4):268. PMID: 23282594.
      Citations:    Fields:    
    494. Fleshner PR, Michelassi F, Rubin M, Hanauer SB, Plevy SE, Targan SR. Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin. Dis Colon Rectum. 1995 Dec; 38(12):1241-5. PMID: 7497833.
      Citations: 9     Fields:    Translation:Humans
    495. Cohen RD, Hanauer SB. Surveillance colonoscopy in ulcerative colitis: is the message loud and clear? Am J Gastroenterol. 1995 Dec; 90(12):2090-2. PMID: 8540493.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    496. Hanauer SB, Schulman MI. New therapeutic approaches. Gastroenterol Clin North Am. 1995 Sep; 24(3):523-40. PMID: 8809234.
      Citations: 1     Fields:    Translation:Humans
    497. Roman-Unfer S, Bitran JD, Hanauer S, Johnson L, Rita D, Booth C, Chen K. Acute myeloid leukemia and myelodysplasia following intensive chemotherapy for breast cancer. Bone Marrow Transplant. 1995 Jul; 16(1):163-8. PMID: 7581117.
      Citations: 1     Fields:    Translation:Humans
    498. Singleton JW, Hanauer S, Robinson M. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease. Dig Dis Sci. 1995 May; 40(5):931-5. PMID: 7729281.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    499. D'Haens GR, Gasparaitis AE, Hanauer SB. Duration of recurrent ileitis after ileocolonic resection correlates with presurgical extent of Crohn's disease. Gut. 1995 May; 36(5):715-7. PMID: 7797122; PMCID: PMC1382675.
      Citations: 8     Fields:    Translation:Humans
    500. Miner P, Hanauer S, Robinson M, Schwartz J, Arora S. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci. 1995 Feb; 40(2):296-304. PMID: 7851193.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    501. Hanauer SB, Baert FJ. The management of ulcerative colitis. Annu Rev Med. 1995; 46:497-505. PMID: 7598482.
      Citations: 2     Fields:    Translation:Humans
    502. Campieri M, Goebell H, Hanauer S, Korelitz B, Lauritsen K, Malchow H, Martin F, Miglioli M, Modigliani R, Present D, Scholmerich J, Sutherland LR. Recommendations for New Trials of Currently Available Therapy by the IOIBD Task Force on Clinical Trials*. Inflamm Bowel Dis. 1995; 1(4):295-8. PMID: 23282431.
      Citations:    Fields:    
    503. Perman E, Hanauer S, Szeless S, Inoue K, Muts-Homsma S, Rahn S. International forum on ulcerative colitis. Risk selection aspects of ulcerative colitis. J Insur Med. 1995; 27(2):167-80. PMID: 15323085.
      Citations:    Fields:    Translation:Humans
    504. Hanauer SB, Baert F. Medical therapy of inflammatory bowel disease. Med Clin North Am. 1994 Nov; 78(6):1413-26. PMID: 7967917.
      Citations: 5     Fields:    Translation:Humans
    505. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994 Jun 30; 330(26):1841-5. PMID: 8196726.
      Citations: 409     Fields:    Translation:HumansCTClinical Trials
    506. Silverstein MD, Lashner BA, Hanauer SB. Cigarette smoking and ulcerative colitis: a case-control study. Mayo Clin Proc. 1994 May; 69(5):425-9. PMID: 8170192.
      Citations: 7     Fields:    Translation:Humans
    507. Hanauer SB. Nicotine for colitis--the smoke has not yet cleared. N Engl J Med. 1994 Mar 24; 330(12):856-7. PMID: 8114839.
      Citations: 4     Fields:    Translation:Humans
    508. Robinson M, Hanauer S, Hoop R, Zbrozek A, Wilkinson C. Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Aliment Pharmacol Ther. 1994 Feb; 8(1):27-34. PMID: 8186343.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    509. Hanauer SB, Krawitt EL, Robinson M, Rick GG, Safdi MA. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group. Am J Gastroenterol. 1993 Sep; 88(9):1343-51. PMID: 8362827.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    510. Hanauer SB. Medical therapy of ulcerative colitis. Lancet. 1993 Aug 14; 342(8868):412-7. PMID: 8101907.
      Citations: 10     Fields:    Translation:Humans
    511. Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, Safdi M. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 1993 Aug; 88(8):1188-97. PMID: 8338086.
      Citations: 69     Fields:    Translation:HumansCTClinical Trials
    512. D'Haens GR, Lashner BA, Hanauer SB. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol. 1993 Aug; 88(8):1174-8. PMID: 8338083.
      Citations: 14     Fields:    Translation:Humans
    513. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol. 1993 May; 88(5):646-9. PMID: 8480725.
      Citations: 28     Fields:    Translation:Humans
    514. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, Krawitt EL. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993 May; 104(5):1293-301. PMID: 8482443.
      Citations: 67     Fields:    Translation:HumansCTClinical Trials
    515. Lashner BA, Shaheen NJ, Hanauer SB, Kirschner BS. Passive smoking is associated with an increased risk of developing inflammatory bowel disease in children. Am J Gastroenterol. 1993 Mar; 88(3):356-9. PMID: 8438840.
      Citations: 17     Fields:    Translation:HumansPHPublic Health
    516. Block GE, Michelassi F, Tanaka M, Riddell RH, Hanauer SB. Crohn's disease. Curr Probl Surg. 1993 Feb; 30(2):173-265. PMID: 8458241.
      Citations: 3     Fields:    Translation:Humans
    517. Smith MB, Hanauer SB. Pneumocystis carinii pneumonia during cyclosporine therapy for ulcerative colitis. N Engl J Med. 1992 Aug 13; 327(7):497-8. PMID: 1625744.
      Citations: 6     Fields:    Translation:Humans
    518. Hanauer S. Primary sclerosing cholangitis and ulcerative colitis: potential cofactors in the dysplasia sequence. Gastroenterology. 1992 Jun; 102(6):2161-2. PMID: 1587440.
      Citations: 2     Fields:    Translation:Humans
    519. Hanauer SB. Relief of functional bowel obstruction. JAMA. 1992 Jan 15; 267(3):414. PMID: 1727970.
      Citations:    Fields:    Translation:Humans
    520. Hanauer SB. Sulfasalazine vs. steroids in Crohn's disease: David vs. Goliath? Gastroenterology. 1991 Oct; 101(4):1130-1. PMID: 1679735.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    521. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, Mekhjian H, Greenberger N, Kelly M, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut. 1991 Sep; 32(9):1071-5. PMID: 1916494; PMCID: PMC1379053.
      Citations: 115     Fields:    Translation:HumansCTClinical Trials
    522. Lashner BA, Hanauer SB. The absence of an association between oral contraceptive use and ulcerative colitis in patients. Gastroenterology. 1991 Jun; 100(6):1784. PMID: 2019387.
      Citations:    Fields:    Translation:Humans
    523. Hanauer SB, Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf. 1991 May-Jun; 6(3):192-219. PMID: 1676590.
      Citations: 13     Fields:    Translation:Humans
    524. Lashner BA, Kane SV, Hanauer SB. Lack of association between oral contraceptive use and ulcerative colitis. Gastroenterology. 1990 Oct; 99(4):1032-6. PMID: 2394326.
      Citations: 2     Fields:    Translation:Humans
    525. Hanauer SB. Aminosalicylates: old and new. Mt Sinai J Med. 1990 Oct; 57(5):283-7. PMID: 1982892.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    526. Lashner BA, Kane SV, Hanauer SB. Colon cancer surveillance in chronic ulcerative colitis: historical cohort study. Am J Gastroenterol. 1990 Sep; 85(9):1083-7. PMID: 2389720.
      Citations: 30     Fields:    Translation:HumansPHPublic Health
    527. Lashner BA, Hanauer SB, Silverstein MD. Testing nicotine gum for ulcerative colitis patients. Experience with single-patient trials. Dig Dis Sci. 1990 Jul; 35(7):827-32. PMID: 2194767.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    528. Lashner BA, Turner BC, Bostwick DG, Frank PH, Hanauer SB. Dysplasia and cancer complicating strictures in ulcerative colitis. Dig Dis Sci. 1990 Mar; 35(3):349-52. PMID: 2307080.
      Citations: 27     Fields:    Translation:Humans
    529. Hanauer SB. The role of mesalazine in Crohn's disease. Scand J Gastroenterol Suppl. 1990; 172:56-9. PMID: 1972296.
      Citations:    Fields:    Translation:Humans
    530. Hanauer SB. Inflammatory bowel disease revisited: newer drugs. Scand J Gastroenterol Suppl. 1990; 175:97-106. PMID: 1978406.
      Citations: 3     Fields:    Translation:Humans
    531. Lashner BA, Kane SV, Hanauer SB. Lack of association between oral contraceptive use and Crohn's disease: a community-based matched case-control study. Gastroenterology. 1989 Dec; 97(6):1442-7. PMID: 2583410.
      Citations: 8     Fields:    Translation:Humans
    532. Lashner BA, Silverstein MD, Hanauer SB. Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance program. Dig Dis Sci. 1989 Oct; 34(10):1536-41. PMID: 2791805.
      Citations: 26     Fields:    Translation:Humans
    533. Lashner BA, Heidenreich PA, Su GL, Kane SV, Hanauer SB. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology. 1989 Aug; 97(2):255-9. PMID: 2568304.
      Citations: 48     Fields:    Translation:HumansPHPublic Health
    534. Hanauer SB. 5-ASA enema therapy. Neth J Med. 1989 Jun; 35 Suppl 1:S11-20. PMID: 2702307.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    535. Thor A, Itzkowitz SH, Schlom J, Kim YS, Hanauer S. Tumor-associated glycoprotein (TAG-72) expression in ulcerative colitis. Int J Cancer. 1989 May 15; 43(5):810-5. PMID: 2654025.
      Citations: 3     Fields:    Translation:Humans
    536. Lashner BA, Evans AA, Hanauer SB. Preoperative total parenteral nutrition for bowel resection in Crohn's disease. Dig Dis Sci. 1989 May; 34(5):741-6. PMID: 2496960.
      Citations: 15     Fields:    Translation:Humans
    537. Silverstein MD, Lashner BA, Hanauer SB, Evans AA, Kirsner JB. Cigarette smoking in Crohn's disease. Am J Gastroenterol. 1989 Jan; 84(1):31-3. PMID: 2912028.
      Citations: 22     Fields:    Translation:Humans
    538. Pamukcu R, Hanauer SB, Chang EB. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid. Gastroenterology. 1988 Oct; 95(4):975-81. PMID: 2842215.
      Citations: 11     Fields:    Translation:Animals
    539. Smith MB, Lashner BA, Hanauer SB. Smoking and inflammatory bowel disease in families. Am J Gastroenterol. 1988 Apr; 83(4):407-9. PMID: 3348193.
      Citations: 4     Fields:    Translation:Humans
    540. Hanauer SB. Fecal incontinence in the elderly. Hosp Pract (Off Ed). 1988 Mar 30; 23(3A):105-8, 111-2. PMID: 3127405.
      Citations:    Fields:    Translation:Humans
    541. Lashner BA, Hanauer SB, Silverstein MD. Optimal timing of colonoscopy to screen for cancer in ulcerative colitis. Ann Intern Med. 1988 Feb; 108(2):274-8. PMID: 3124681.
      Citations: 14     Fields:    Translation:Humans
    542. Lashner BA, Evans AA, Kirsner JB, Hanauer SB. Prevalence and incidence of inflammatory bowel disease in family members. Gastroenterology. 1986 Dec; 91(6):1396-400. PMID: 3770366.
      Citations: 25     Fields:    Translation:Humans
    543. Lashner BA, Todorczuk J, Sahm DF, Hanauer SB. Clostridium difficile culture-positive toxin-negative diarrhea. Am J Gastroenterol. 1986 Oct; 81(10):940-3. PMID: 3766495.
      Citations: 12     Fields:    Translation:Humans
    544. Lashner BA, Kirsner JB, Hanauer SB. Acute pancreatitis associated with high-concentration lipid emulsion during total parenteral nutrition therapy for Crohn's disease. Gastroenterology. 1986 Apr; 90(4):1039-41. PMID: 3081397.
      Citations: 10     Fields:    Translation:Humans
    545. Bengoa JM, Hanauer SB, Sitrin MD, Baker AL, Rosenberg IH. Pattern and prognosis of liver function test abnormalities during parenteral nutrition in inflammatory bowel disease. Hepatology. 1985 Jan-Feb; 5(1):79-84. PMID: 3917969.
      Citations: 5     Fields:    Translation:Humans
    546. Kirsner JB, Hanauer SB. Crohn's disease. The problem and its management. Hosp Pract (Off Ed). 1984 Jul; 19(7):121-32, 135-6, 141-2. PMID: 6429165.
      Citations:    Fields:    Translation:Humans
    547. Kirsner JB, Deutsch S, Hanauer SB. Selected individual therapeutic problems in inflammatory bowel disease. Am J Gastroenterol. 1984 May; 79(5):368-75. PMID: 6144267.
      Citations:    Fields:    Translation:Humans
    548. Yuan SZ, Hanauer SB, Kluskens LF, Kraft SC. Circulating lymphocyte subpopulations in Crohn's disease. Gastroenterology. 1983 Dec; 85(6):1313-8. PMID: 6605274.
      Citations: 13     Fields:    Translation:HumansCells
    549. Hanauer SB, Wong KK, Frank PH, Sweet DL, Kirsner JB. Acute leukemia following inflammatory bowel disease. Dig Dis Sci. 1982 Jun; 27(6):545-8. PMID: 6953008.
      Citations: 11     Fields:    Translation:Humans
    550. Yung CW, Hanauer SB, Fretzin D, Rippon JW, Shapiro C, Gonzalez M. Disseminated Trichosporon beigelii (cutaneum). Cancer. 1981 Nov 01; 48(9):2107-11. PMID: 6945903.
      Citations: 8     Fields:    Translation:HumansAnimals
    551. Golomb HM, Hanauer SB. Infectious complications associated with hairy cell leukemia. J Infect Dis. 1981 May; 143(5):639-43. PMID: 7240806.
      Citations: 7     Fields:    Translation:Humans
    Hanauer's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (935)
    Explore
    _
    Co-Authors (40)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _